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General introduction
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Breast cancer is the most diagnosed type of cancer in women worldwide, with an incidence of 
nearly 1.7 million new cases diagnosed in 20121. Breast cancer represents approximately 12% 
of all new cancer cases and 25% of all cancers in women1. In the Netherlands, the incidence 
of breast cancer has increased over the years, while mortality has decreased. In 2014, 14.556 
women were diagnosed with invasive breast cancer, while 3.041 women died because of breast 
cancer in the same year2. Because of screening and improvements in treatment options, the 
5-year overall survival rate of breast cancer in the Netherlands increased from 77% for patients 
diagnosed between 1989 and 1993 to 87% for patients diagnosed between 2008 and 2012 
(figure 1.1)2-4.
Figure 1.1. The overall survival rate for breast cancer patients in the Netherlands for different periods of 
diagnosis based on data from the Dutch cancer registry2 
Treatment for early stage breast cancer consists of surgery, mostly in combination with 
radiotherapy, chemotherapy, endocrine therapy, targeted and/or immunotherapy. 
Chemotherapy regimens changed from cyclophosphamide, methotrexate and 5-fluorouracil 
(CMF) in the 1970s and 1980s, to anthracyclines in the 1990s, to combination regimes including 
taxanes in the 2000s5-7. Currently, chemotherapy for breast cancer mostly consists of third 
generation schemes which combine anthracyclines (e.g. doxorubicin, epirubicin) and taxanes 
(e.g. paclitaxel, docetaxel) with or without trastuzumab. In the Dutch cancer clinical practice 
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guidelines, the type of chemotherapy recommended depends on several factors, such as age, 
size of tumour, involved lymph nodes and HER-2 status8. Table 1.1 gives an overview of the 
currently recommended chemotherapy regimens for early breast cancer in the Netherlands by 
HER-2 status8.
Table 1.1. Currently recommended chemotherapy treatment regimens for early stage breast cancer in the 
Netherlands8
HER-2 status Regime Scheme of treatment 
 TAC 6 times docetaxel, doxorubicin and cyclophosphamide every 3 
weeks  
HER-2
 FEC/DOC 3 times fluorouracil, epirubicin and cyclophosphamide every 3 
weeks, followed by 3 times docetaxel every 3 weeks 
negative
 AC/P(T) 4 times doxorubicin and cyclophosphamide every 3 weeks  followed 
by 12 times paclitaxel   
 AC/DOC/(T) 4 times doxorubicin and cyclophosphamide every 3 weeks  followed 
by 4 times docetaxel  
HER-2
 AC/P(T) 4 times doxorubicin and cyclophosphamide every 3 weeks  followed 
by 12 times paclitaxel with trastuzumab every week
positive
 AC/DOC/(T) 4 times doxorubicin and cyclophosphamide every 3 weeks  followed 
by 4 times docetaxel with trastuzumab every 3 weeks
Because of the improved survival rate, short and long term adverse effects of treatment have 
become increasingly important. Body weight and body composition before, during and after 
chemotherapy may affect side effects during treatment and survival. In the next paragraphs this 
will be discussed further.
Body weight and body composition at diagnosis
High BMI or obesity before diagnosis of breast cancer is consistently associated with increased risk 
of overall and breast cancer specific mortality in meta-analyses9-12. Knowledge of the association 
between pre-diagnosis body composition and survival is limited. Several studies suggest that a 
higher waist-hip ratio is associated with an increased risk of breast cancer mortality, although 
results are inconsistent13-18. 
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Body weight and body composition have not only been associated with survival; studies in 
other types of cancer suggest that pre-diagnosis body composition may also affect the risk 
of  chemotherapy-induced toxicity. Severe toxicities during chemotherapy may lead to a 
postponement of treatment, dose reduction or a premature termination of the treatment. 
These changes in treatment eventually may lead to a lower total administered dose, and worse 
outcome19. Studies of other cancer types have shown that chemotherapy-induced toxicity is 
highest in patients with a low lean body mass20-25. 
In metastatic breast cancer, patients with sarcopenia, low muscle mass, or low lean body mass 
are at an increased risk of dose limiting toxicity during chemotherapy. Body composition of 
patients with metastatic disease may be affected by disease-related sarcopenia and/or cachexia. 
Therefore it is unclear whether findings in metastatic breast cancer are generalizable to early 
stage breast cancer. One of the aims of this thesis was to assess the association between pre-
treatment body composition and dose-limiting toxicities during chemotherapy in early stage 
breast cancer patients. 
Changes in body weight and body composition during chemotherapy
Several narrative reviews report weight gain in women with breast cancer during 
chemotherapy26-32. Mid-1990s reviews of the literature suggest that significant weight gain 
occurred in 50-96% of the breast cancer patients who received chemotherapy. Weight gain 
was reported to vary from 2.5 to 6.2kg, while gains of more than 10 kg were not unusual27,28,33. 
More recent studies report a lower prevalence of weight gain (35-85%), with weight gain 
varying between 1.4 and 5.0 kg34-39. 
There are important methodological differences between the studies published so far, which 
makes it difficult to compare results. These differences include the type of chemotherapy 
treatment, characteristics of the study participants, timing of the measurements of body weight, 
and the study design. As no meta-analyses among changes in body weight during chemotherapy 
are currently available, this thesis includes a meta-analysis on changes in body weight during 
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chemotherapy, taking variables which may explain heterogeneity between studies into account.
 
Weight gain during chemotherapy is associated with worse quality of life and self-esteem30,31. In 
addition, several studies have reported that weight gain may be associated with an increased 
risk of disease recurrence and poorer prognosis, however, these results are inconsistent30,31,40-44. 
A recent meta-analysis concluded that a weight gain of 10% or more after diagnosis of breast 
cancer is associated with higher all-cause mortality, although mainly due to one study45. These 
results suggest the importance of further investigation of weight changes during chemotherapy.
Potentially unfavourable changes in body composition may also occur during chemotherapy. 
Changes observed consist of an increase in fat mass with a loss or no change in lean body mass, 
sometimes even without weight gain29-32. Previous studies of changes in body composition were 
hampered by a small size and lack of a comparison group of women without breast cancer. 
Without a comparison group it is impossible to assess whether changes in body composition 
in breast cancer patients during chemotherapy are indeed treatment related or regular age-
related changes. One of the aims of this thesis was therefore to obtain more insight in changes 
in body weight and body composition during chemotherapy in women with early stage breast 
cancer.  
Determinants associated with changes in body weight and body composition 
during treatment
To date, it is not clear which determinants underlie the changes in body weight and body 
composition during chemotherapy in breast cancer patients. Several possible determinants 
have been described, such as treatment-induced ovarian failure accompanied by the rapid onset 
of menopause46, menopausal status at diagnosis30,31,47,48, age at diagnosis30,39,49, BMI, fat mass 
and body weight before start of chemotherapy30,50,51, and resting energy expenditure27,36,37,52. 
In addition, several studies described reductions in physical activity during and after 
treatment26,31,37,49,53.
Previous studies which investigated whether dietary intake changed during chemotherapy in 
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breast cancer patients produced inconsistent results. These results either showed increases54, 
decreases27,55 or no changes26,36,52 in energy intake during chemotherapy, possibly because 
different studies used different methods and different time points during the course of 
chemotherapy to assess energy intake. Therefore we aimed to assess differences in dietary 
intake during chemotherapy between women with breast cancer and a comparison group of 
women without cancer.
Besides the meta-analysis of previous studies, we conducted an observational study among 
breast cancer patients stage I-IIIB and among an age-matched comparison group of women 
without cancer to assess changes in body weight and body composition during chemotherapy, 
named the COBRA-study (Change Of Body composition in Breast cancer: All-in assessment). 
The COBRA-study
The COBRA-study is a prospective study of newly diagnosed, operable, stage I-IIIB breast cancer 
patients scheduled for chemotherapy and a comparison group of women without diagnosed 
cancer of a similar age (range +/- 2 years). Patients were followed from before chemotherapy 
until a half year after chemotherapy. Women in the comparison group were followed until a year 
after inclusion. Eligible patients were recruited by the staff of 11 participating hospitals in the 
Netherlands prior to commencement of chemotherapy. Participants in the comparison group 
were recruited via patients, who were asked to distribute envelopes with study information to 
friends, acquaintances and colleagues. Women without cancer interested in participating in the 
study could contact the researchers. All study participants needed to be at least 18 years old and 
able to communicate in Dutch. Exclusion criteria were: history of cancer, previous treatment with 
chemotherapy, pregnancy or the intention to get pregnant during the study period, dementia or 
other mental conditions that made it impossible to comply with the study procedures. The study 
design consist of different moments of measurement, see figure 1.2.
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 Patient Baseline Chemotherapie Measurements shortly Measurements 6 months group measurements  after chemotherapy after chemotherapy
  Measurements Measurements Measurements Measurements
  - DEXA-scan - 2x24-hr recall - DEXA-scan - DEXA-scan
  - FFQ  - Physical activity - FFQ
  - General questionnaire  - Physical activity
  - Physical activity
 Comparison Baseline  Measurrements 6 Measurements 12
 group measurements  months after baseline months after baseline
Figure 1.2. Study design of the COBRA-study
Aim and outline of this thesis
The aims of this thesis are, to assess among patients with stage I-IIIB breast cancer:
1. the association between pre-treatment body composition and dose-limiting toxicities du-
ring chemotherapy.
2. potential changes in body weight and body composition during and after chemotherapy 
compared to changes in age-matched women without cancer in the same time period. 
3. dietary intake during chemotherapy compared to age-matched women without cancer in 
the same time period.
Chapter 2 describes the association between pre-treatment body composition and dose-
limiting toxicities during chemotherapy in early stage breast cancer patients found within the 
COBRA-study. Chapter 3 presents the results of a meta-analysis to quantify changes in body 
weight during chemotherapy in early stage breast cancer patients and to identify which factors 
contribute to the heterogeneity between studies. Chapter 4 presents the results of the COBRA-
study, investigating changes in body composition during treatment in breast cancer patients 
compared to women of a similar age without cancer and the determinants associated with these 
changes. Chapter 5 describes the differences in dietary intake during chemotherapy treatment 
in breast cancer patients compared with women without cancer in the COBRA-study. In the 
final chapter of this thesis, Chapter 6, the main findings of the chapters are summarized and 
discussed. This chapter also includes recommendations for clinical practice and future research.
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Abstract 
Purpose: The initial dose of chemotherapy is calculated based on body surface area, which does 
not take body composition into account. The aim of this study was to assess the association 
between fat mass (kg and relative to total body weight), lean body mass (kg and relative to 
total body weight), and risk of dose-limiting toxicities defined as dose reductions, cycle delays or 
premature termination of chemotherapy in breast cancer patients.
Methods: Data were included from 172 women with breast cancer (stage I-IIIB) treated 
with chemotherapy. Body composition was assessed using a total body Dual-Energy X-ray 
Absorptiometry scan. Information regarding dose-limiting toxicities was abstracted from medical 
records. Prevalence ratios were calculated to assess the association between body composition 
and the risk of dose-limiting toxicity. All analyses were adjusted for age. 
Results: 95 out of 172 patients experienced dose-limiting toxicity (55%). Higher BMI was 
associated with a higher risk of dose-limiting toxicity (PR 1.04 per kg/m2; 95%CI 1.01-1.06). Similar 
results were found for a higher fat mass (kg and percentage) (PR: 1.08 per 5 kg; 95%CI 1.03-1.14 
and PR 1.13 per 5 percent; 95%CI 1.04-1.24, respectively). Higher percentage lean body mass 
was associated with a lower risk of dose-limiting toxicity (PR 0.88 per 5 percent; 95%CI 0.80-
0.97). There was no association between lean body mass (kg) and risk of dose-limiting toxicities.
Conclusion: A higher BMI and a higher fat mass (kg and percentage) are associated with an 
increased risk of dose-limiting toxicity, while lean body mass (kg) is not associated with risk of 
toxicities. These data suggest that total fat mass more strongly determine the risk of dose-limiting 
toxicities during chemotherapy in breast cancer patients. Future studies are needed to confirm 
these results of an association of fat mass with dose-limiting toxicities during chemotherapy.
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Introduction
Breast cancer patients are often treated with chemotherapy, which usually consist of a combination 
of anthracyclines (e.g. doxorubicin, epirubicin) and taxanes (e.g. paclitaxel, docetaxel) with or 
without targeted therapy1. Severe side effects during chemotherapy can lead to a dose reduction, 
cycle delay, or premature termination of treatment, commonly referred to as dose-limiting toxicity, 
which eventually may lead to a reduced dose intensity, and worse outcome2.
In clinical practice, the administered dose of the chemotherapy is based on the body surface 
area (BSA). BSA is usually calculated using the Mosteller formula based on height and weight3; it 
does not distinguish lean body mass from fat mass or other characteristics of body composition. 
It has been suggested that body composition may be more important than body surface area for 
calculating the administered dose of chemotherapy, since previous studies in other cancer types 
showed that patients with low lean body mass have a higher risk of a dose limiting toxicity4-9. 
In metastatic breast cancer, patients with sarcopenia or low muscle mass or low lean body mass 
are at an increased risk of dose-limiting toxicity during chemotherapy10-12. Body composition 
of metastatic breast cancer patients generally differs from early stage breast cancer patients, 
because of disease related sarcopenia and/or cachexia. Therefore, findings in metastatic breast 
cancer may not be generalizable to early stage breast cancer10,12,13. 
So far, only two studies focused on treatment-related toxicities in early stage breast cancer 
patients were published. These studies showed that a lower lean body mass was associated with 
an increased risk of toxicities14,15. 
The aim of this paper was to assess the association between fat mass, lean body mass, and the risk of 
a dose-limiting toxicity in women with breast cancer stage I-IIIB receiving neo-adjuvant chemotherapy.  
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Materials and Methods
Participants
This study is part of the COBRA-study, an observational multi-centre study among breast cancer 
patients receiving neo-adjuvant chemotherapy16. Eligible patients were recruited by the medical 
staff from 11 academic and peripheral hospitals in the Netherlands prior to commencement 
of chemotherapy. Women were eligible if they were newly diagnosed with operable stage I-IIIB 
breast cancer, and scheduled for 2nd or 3rd generation neo-adjuvant chemotherapy. Participants 
needed to be at least 18 years old and be able to communicate in Dutch. Exclusion criteria 
were: history of cancer, previous treatment with chemotherapy, (intended) pregnancy during 
the study period, dementia or other mental conditions that made it impossible to comply with 
the study procedures. 
For the current analyses, data were available for 176 breast cancer patients of the COBRA-study 
recruited between May 2013 and September 2016. Four patients had to be excluded, because 
they had no Dual-Energy X-ray Absorptiometry (DEXA)-scan available. In total we considered 172 
participants for the analyses for this study. 
The study protocol was approved by the Medical Ethical Committee of Wageningen University, 
the Netherlands. All participants provided written informed consent before enrolment.
Data collection
Body composition
Body composition was assessed using a DEXA-scan. Participants were measured in the hospitals 
by trained technicians using a total body scan protocol prior to start of chemotherapy (n=86) or 
during the first cycle of chemotherapy (n=86). Based on the total body DEXA-scan body weight 
(kg), fat mass (kg and relative to total body weight), and lean body mass (kg and relative to total 
body weight) were assessed. 
Treatment-related toxicity
Information regarding chemotherapy and toxicity was abstracted from medical records using 
a standardized form. Treatment information included detailed information on type and dose 
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of chemotherapy, number of cycles planned, and start dates of each cycle. Furthermore, 
information on actual administered dose, toxicities and reasons for a dose-limiting toxicity were 
collected per cycle. Dose-limiting toxicities were defined as dose reductions, cycle delays or 
premature termination of chemotherapy. Also, if a planned cytotoxic regime was changed to 
another regime because of toxicities, this was reported as a dose-limiting toxicity. If the reason 
for a dose reduction or cycle delay was unknown (n=4) we included them as dose-limiting 
toxicity. Logistical or other non-medical reasons for cycle delays were not classified as a dose-
limiting toxicity. 
Patient and clinical characteristics
Information about tumour stage at diagnosis and timing of chemotherapy (adjuvant versus neo-
adjuvant) was collected from medical records. Information regarding age at cancer diagnosis 
and height were collected using a general questionnaire. Based on body weight of the DEXA-
scan and self-reported height, BMI at diagnosis was calculated. Chemotherapy regimens were 
categorized as combined and sequential regimes (supplementary table 2.1); combined regimes 
included schemes with different components administered together during all cycles, and 
included TAC, FEC, DOC-CYCLO, CDT(P) PT, and CTP. Sequential regimes included schemes with 
different components that were administered in different cycles and included AC/P(T), FEC/DOC, 
and AC/DOC/(T).
 
Data analysis
Population characteristics are presented as median with interquartile range (IQR) or number 
with percentage for the total study population, and participants experiencing a dose-limiting 
toxicity (yes versus no) separately. 
Prevalence ratios (PRs) including 95% confidence intervals (CI) were calculated to assess the 
association between body composition and the occurrence of dose-limiting toxicity (yes versus 
no) using a Cox proportional hazard regression model with a fixed time17. For all analyses 
separate models were built for each body composition parameter, i.e. BMI (kg/m2), fat mass per 
5 percent, fat mass per 5 kg, lean body mass per 5 percent, and lean body mass per 5 kg. 
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Stratified analyses were conducted for patients receiving a sequential regime versus a combined 
regime, and for patients receiving adjuvant chemotherapy versus neo-adjuvant chemotherapy. 
A sensitivity analysis was conducted for dose-limiting toxicities occurring within the first 6 cycles 
of chemotherapy. This was done to account for the fact that patients with a higher number 
of cycles planned have higher odds of experiencing toxicities as they go through more cycles. 
In this sensitivity analysis, only dose-limiting toxicities occurring within the first 6 cycles were 
considered.
Analyses were adjusted for age, since older women have an increased risk of experiencing 
toxicities and age is associated with specific body composition characteristics18. Based on 
literature, BSA was considered as potential covariate, but not included in the analyses since BSA 
was strongly related with the body composition parameters (multicolinearity). All analyses were 
performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA).
 
Results
Patient characteristics
The median age of the 172 women included was 51.8 years (table 2.1). More than half of 
the participants were overweight or obese at diagnosis. Most patients had a stage II tumour, 
received adjuvant chemotherapy with a sequential regime consisting of 6 or less planned cycles. 
Table 1 shows that women experiencing a dose-limiting toxicity were more often treated with 
a sequential regime of adjuvant chemotherapy compared to the women not experiencing a 
dose-limiting toxicity. In addition, women experiencing a dose-limiting toxicity had a higher body 
weight, were more often overweight or obese, had a higher fat mass and lower percentage of 
lean body mass compared to the women not experiencing a dose-limiting toxicity.
Frequency of first dose-limiting toxicities 
Table 2.2 shows the frequency of first dose-limiting toxicities. During chemotherapy, more than 
half of the patients experienced a dose-limiting toxicity (95 out of 172 patients, 55%). Of these 
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95 patients, 14% (n=13) stopped prematurely, 53% (n=50) had a dose reduction and 34% (n=32) 
had a cycle delay as their first dose-limiting toxicity. In total, 48% (n=57) of the women receiving 
6 or less planned cycles experienced a dose-limiting toxicity versus 72% (n=38) of the women 
receiving more than 6 planned cycles. 
 
Table 2.1. Demographic and clinical characteristics of the patient group included in the study.ble 2.2.       
   Abbreviations; IQR Interquartile range; 95% CI 95% confidence interval; BMI body mass index; 
Table 2.1. Demographic and clinical characteristics of the patient group included in the study. 
Characteristics 
Total 
(n=172) 
Dose-limiting 
toxicity yes 
(n=95) 
Dose-limiting 
toxicity no 
(n=77) 
Demographics 
Age, years (median, IQR) 
 
51.8 (46.8 ; 59.1) 
 
52.1 (47.4 ; 60.8) 
 
51.5 (46.4 ; 54.6) 
Medical profile    
Stage (n, %) 
I 
II  
III 
 
44 (25.6) 
105 (61.1) 
23 (13.4) 
 
26 (27.4) 
57 (60.0) 
12 (12.6) 
 
18 (23.4) 
48 (62.3) 
11 (14.3) 
Chemotherapy (n, %) 
Adjuvant 
Neo-adjuvant 
 
111 (64.5) 
61 (35.5) 
 
67 (70.5) 
28 (29.5) 
 
44 (57.1) 
33 (42.9) 
Type of chemotherapy (n, %) 
Combined regime 
Sequential regime 
 
78 (45.3) 
94 (54.7) 
 
36 (37.9) 
59 (62.1) 
 
42 (54.6) 
35 (45.5) 
Number of cycles chemotherapy (n, %) 
6 or less 
More than 6 
 
119 (69.2) 
53 (30.8) 
 
57 (60.0) 
38 (40.0) 
 
62 (80.5) 
15 (19.5) 
Body composition    
Body weight, kg (median, IQR) 70.5 (63.9 ; 81.7) 74.1 (64.4 ; 84.6) 68.2 (63.1 ; 76.1) 
Body height, cm (median, IQR) 168 (164 ; 173) 168 (162 ; 173) 168 (164 ; 173) 
Body surface area (BSA), (median, IQR) 1.8 (1.7 ; 2.0) 1.8 (1.7 ; 2.0) 1.8 (1.7 ; 1.9) 
Body Mass Index (BMI) kg/m2 (median, IQR) 25.5 (22.5 ; 29.1) 26.5 (23.9 ; 29.8) 24.5 (21.7 ; 27.2) 
Fat mass, percentage (median, IQR) 36.7 (31.4 ; 42.2) 38.6 (33.7 ; 44.8) 35.0 (29.7 ; 39.9) 
Fat mass, kg (median, IQR) 26.0 (20.2 ; 34.2) 27.6 (20.8 ; 36.3) 23.1 (18.4 ; 31.1) 
Lean body mass, percentage (median, IQR) 60.2 (33.2 ; 65.1) 58.5 (53.1 ; 63.5) 61.8 (57.2 ; 66.7) 
Lean body mass, kg (median, IQR) 43.1 (29.4 ; 46.8) 43.1 (39.5 ; 47.5) 42.8 (39.3 ; 46.6) 
Appendicular skeletal mass, kg (median, IQR) 18.2 (16.8 ; 20.2) 18.2 (16.6 ; 20.2) 18.2 (16.9 ; 20.1) 
Skeletal muscle index, kg/m2 (median, IQR) 6.5 (6.0 ; 7.2) 6.5 (6.0 ; 7.3) 6.4 (6.0 ; 7.1) 
Abbreviations; IQR Interquartile range; 95% CI 95% confidence interval; BMI body mass index;  
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Table 2.2.Frequencies of first dose limiting toxicities experienced by patients.
   Results are presented for all patients and stratified by number of cycles. Presented as number and percentage.
BMI and body composition and risk of dose-limiting toxicity 
A higher BMI was associated with a higher risk of a dose-limiting toxicity (PR 1.04 per kg/m2; 
95%CI 1.01-1.06) as was a higher fat mass and fat percentage (PR: 1.08 per 5 kg; 95%CI 1.03-1.14 
and PR 1.13 per 5 percent; 95%CI 1.04-1.24, respectively), see table 2.3. A higher percentage of 
lean body mass was associated with a lower risk of a dose-limiting toxicity (PR 0.88 per 5 percent; 
95%CI 0.80-0.97). The body composition indicator lean body mass in kg was not associated with 
dose limiting toxicity (table 2.3). 
Sensitivity and stratified analyses
Figure 2.1 shows the time in cycle numbers until the occurrence of the first dose-limiting toxicity. 
In total, 73 of the 95 women (77%) experienced their first dose-limiting toxicity within the first 
6 cycles of chemotherapy. Sensitivity analyses including only dose-limiting toxicities occurring 
within the first 6 cycles showed similar results compared to the analysis in which we included 
dose-limiting toxicities in all cycles (table 2.3).
Stratified results did not suggest that the associations between body composition and dose-
limiting toxicity was different for combined versus sequential regimes, nor for neo-adjuvant 
versus adjuvant chemotherapy (data not shown).
 
Table .2. Frequencies of first dose limiting toxiciti  tients.  
Toxicity 
All patients 
(n=172) 
6 planned cycles 
or less 
(n=119) 
More than 6  planned 
cycles 
(n=61) 
Any dose-limiting toxicity 95 (55.2) 57 (47.9) 38 (71.7) 
Cycle delay 32 (33.7) 17 (29.8) 15 (39.5) 
Dose reduction 50 (52.6) 36 (63.2) 14 (36.8) 
Premature termination 13 (13.7) 4 (7.0) 9 (23.7) 
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Table 2.3. Association between body composition parameters and occurrence of any dose-limiting toxicity 
or time to first dose-limiting toxicity for all included patients and results of the sensitivity within the first 6 
cycles of chemotherapy. Presented as prevalence or hazard ratios adjusted for age.
 
    Abbreviations; PR prevalence ratio; CI 95% confidence interval; BMI body mass index; 
* p <0.05
Figure 2.1. Time to first dose-limiting toxicity in cycle numbers, stratified for patients receiving a cytotoxic 
scheme consisting of 6 or less cycles and patients receiving a cytotoxic scheme consisting of more than 6 cycles.
 
 
Figure 2.1. Time to first dose-limiting toxicity in cycle numbers, stratified for patients receiving a cytotoxic scheme 
consisting of 6 or less cycles and patients receiving a cytotoxic scheme consisting of more than 6 cycles. 
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Table 2.3. Association between body composition parameters and occurrence of any dose-limiting toxicity or 
time to first dose-limiting toxicity for all included patients and result  of the sensitivity within t e first 6 cycles 
of chemotherapy. Present d as prevalence or hazard ratios adjusted for age. 
All included participants 
 Total/cases Occurrence of a dose-limiting toxicity 
Variable  PR 95% CI 
BMI per kg/m2 * 172/95 1.04 1.01 ; 1.06 
Fat mass per 5 percent* 172/95 1.13 1.04 ; 1.24 
Fat mass per 5 kg* 172/95 1.08 1.03 ; 1.14 
Lean mass per 5 percent* 172/95 0.88 0.80 ; 0.97 
Lean mass per 5 kg 172/95 1.05 0.95 ; 1.17 
Appendicular skeletal mass per kg 172/95 1.01 0.96 ; 1.06 
Skeletal muscle Index per kg/m2 172/95 1.06 0.91 ; 1.23 
Sensitivity analyses 
 Total/cases Occurrence of a dose-limiting toxicity 
Variable  PR 95% CI 
BMI per kg/m2* 172/73 1.04 1.01 ; 1.07 
Fat mass per 5 percent* 172/73 1.14 1.01 ; 1.28 
Fat mass per 5 kg* 172/73 1.09 1.02 ; 1.17 
Lean mass per 5 percent* 172/73 0.88 0.77 ; 1.00 
Lean mass per 5 kg 172/73 1.07 0.94 ; 1.22 
Appendicular skeletal mass per kg 172/73 1.02 0.97 ; 1.08 
Skeletal muscle index per kg/m2 172/73 1.11 0.92 ; 1.33 
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Discussion
This study shows that a higher total fat mass in kg and percentage, and a lower percentage of 
lean body mass were associated with an increased risk of dose-limiting toxicity in breast cancer 
patients stage I-IIIB treated with chemotherapy, while lean body mass in kg was not associated 
with dose-limiting toxicities. Our results suggest fat mass strongly determine the risk of dose-
limiting toxicities during chemotherapy in breast cancer patients.
In contrast, two earlier studies14,15 stressed the importance of total lean body mass in the 
association with chemotherapy-induced toxicities. However, these studies did not assess 
chemotherapy-induced toxicities in association with relative lean body mass or total fat mass 
(kg or percentage). The first study (n=151) used CT-scans to assess body composition and 
concluded that lower total lean body mass and skeletal muscle gauge – a composite endpoint 
of muscle mass and muscle radio density - were associated with increased risk of treatment-
related grade 3-4 toxicities in patients receiving doxorubicin-cyclophosphamide (AC)-taxane 
based cytotoxic regimens14. The second study (n=24) concluded that a lower total lean body 
mass was associated with higher incidence of dose-limiting toxicities during the first cycle of 
FEC10015, again with CT-scan as measurement of body composition. Both studies extrapolated 
total lean body mass from skeletal muscle cross-sectional area of a CT-scan at the level of the 
third vertebrae, but did not report results of toxicity associations with percentage of total lean 
body mass or fat mass. Moreover, the study populations of both studies differed from our 
population, making it challenging to compare the results. For example, in the study of Prado 22 
out of 24 patients experienced a dose-limiting toxicity during the first cycle of chemotherapy15, 
which is considerably more than our study where 15 out of 172 patients had a toxicity during the 
first cycle. This suggests that the selection process of participants eligible for their study led to a 
group patients at high risk of toxicities which may impact the generalizability of those findings. In 
the study by Sachar et al, the average of BMI was 2 to 3 kg/m2 higher than in our study, while lean 
body mass was slightly lower14. Baseline differences in body composition between studies plus 
a different outcome measure to assess toxicities obstruct direct comparison between studies.
Possible mechanisms for the observed association between body composition and chemotherapy-
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induced toxicities are unclear, but could be either biological or clinical. Depending on the type of 
cytotoxic agent, drugs may be more hydrophilic or hydrophobic which will affect the clearance 
and volume of distribution of the drugs. For hydrophilic drugs, it has been hypothesized that 
patients with a relatively lower lean body mass may be overdosed when using body surface area 
to calculate dosage, and may present with higher rates of dose-limiting toxicities.  In our study, 
it was not possible to stratify on type of chemotherapy, because of power. However, stratified 
results did not suggest that associations between body composition and dose-limiting toxicity 
were different for combined versus sequential regimes.
A more clinical, although speculative explanation for a higher risk of toxicities in patients with low 
lean body mass could be that clinicians treat patient with a lower percentage of lean body mass 
differently than patients with a higher percentage lean body mass, although this is not formally 
assessed. Patients with a low lean body mass may be frailer, and may generally experience other 
comorbidities, which could prompt the medical oncologist to adapt the chemotherapy protocol 
earlier than patients with a better physical condition.  
In conclusion, a higher BMI and a higher fat mass (kg and percentage) are associated with 
an increased risk of dose-limiting toxicity, while lean body mass (kg) was not associated with 
risk of toxicities. This suggest that total fat mass more strongly determine the risk of dose-
limiting toxicities during chemotherapy in breast cancer patients. Future studies are needed 
to confirm these results of an association of fat mass with dose-limiting toxicities during 
chemotherapy.
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Supplementary table 2.1. Chemotherapy schemes included in the study
 Chemotherapy Scheme
 TAC 6 times docetaxel, doxorubicin and cyclophosphamide every 
  3 weeks
Combined
  FEC 6 times fluorouracil, epirubicin and cyclophosphamide every 
  3 weeks
regimens
 DOC-CYCLO 6 times docetaxel and cyclophosphamide 
  every 3 weeks
 CDT(P) 6 times carboplatin, docetaxel and trastuzumab with or without 
pertuzumab every 3 weeks
 PT 12 times paclitaxel and trastuzumab every week
 CTP 18 times carboplatin, paclitaxel and trastuzumab, 
  every week
 AC/P(T) 4 times doxorubicin and cyclophosphamide every 3 weeks followed 
by 12 times paclitaxel with or without trastuzumab every week
Sequential
 FEC/DOC times fluorouracil, epirubicin and cyclophosphamide every 
  3 weeks, followed by 3 times docetaxel every 3 weeks
regimes 
 AC/DOC/(T) 4 times doxorubicin and cyclophosphamide every 
  3 weeks followed by 4 times docetaxel with or without 
  trastuzumab every 3 weeks
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Abstract
Background: Weight gain during chemotherapy in women with breast cancer is commonly 
reported. However, there are important differences between studies that examined weight 
change during chemotherapy; e.g. type of chemotherapy, menopausal status, time between 
body weight measurements and sample size. The purpose of this meta-analysis was to quantify 
changes in body weight during chemotherapy for women with breast cancer, taking these 
differences into account. 
Method and materials: We identified relevant studies using PubMed, Scopus and Embase 
databases. The search was limited to human studies published in English up to and including 
December 2015. Only studies among women with early stage breast cancer treated with 
chemotherapy, with reported body weight before and after chemotherapy and type of 
chemotherapy were included. Random-effect models were used, and heterogeneity between 
studies was explored through stratified analyses and meta-regression. Sensitivity analyses were 
done to explore whether a specific study markedly affected the results.
Results: In total 25 papers were found, including data from 2620 women. Overall, body weight 
increased during chemotherapy: 2.7kg (95% CI 2.0, 7.5 ) with a high degree of heterogeneity 
(I2= 94.2%). Stratified analyses showed weight gain in all strata, but did not substantially reduce 
heterogeneity. Univariate meta-regression showed less weight gain in prospective studies 
compared to chart review studies (-2.0, 95%CI: -3.1, -0.8). Studies including cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF) regimes showed a greater weight gain compared to those 
that did not (2.2, 95%CI: 1.1, 3.3); and papers published until the year 2000 showed a greater 
weight gain compared to those published after 2000 (1.9, 95%CI:-0.8, 3.1). In the multivariate 
models only studies including CMF regimes and studies published until 2000 were associated 
with significant weight gain of respectively 1.3 and 1.4kg.
Conclusion: Despite the high heterogeneity, this meta-analysis shows significant weight gain 
during chemotherapy for women with breast cancer. Weight gain was more pronounced in 
papers published until 2000 and women receiving CMF as chemotherapy regime. Although 
weight gain after chemotherapy has decreased over the course of time, weight gain is still 
substantial and deserves clinical attention.
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Introduction
Treatment for early stage breast cancer mostly consists of a combination of surgery, radiotherapy, 
chemotherapy and hormonal therapy. Chemotherapy can cause various side effects, such as 
nausea, vomiting, hair loss, fatigue, mucositis, cytopenia, ovarian failure and cardiac toxicity. In 
addition, numerous studies have described weight gain in women with breast cancer during 
chemotherapy1-8. 
Several reviews reported body weight gain during chemotherapy for breast cancer patients9-15. 
Weight gain during chemotherapy was first reported in 1978 by Dixon et al16. Mid-1990s reviews 
of the literature suggest that significant weight gain occurred in 50-96% of the breast cancer 
patients who received chemotherapy. Weight gain was reported to vary from 2.5 to 6.2 kg, while 
gains of more than 10kg were not unusual13,14,17.  More recent studies report a lower prevalence 
of weight gain (35-85%), with weight gain varying between 1.4 to 5.0 kg6-8,18-20. 
Body weight gain during chemotherapy treatment for breast cancer is undesirable, since it has 
negative influences on quality of life and health. Weight gain during treatment is associated with a 
negative affect on quality of life and self-esteem. In addition, several studies reported an increased 
risk of disease recurrence and poorer prognosis, however, these results are inconsistent10,15,21-25. A 
recent meta-analysis concluded that a weight gain of 10% or more after diagnosis of breast cancer 
is associated with higher all-cause mortality, mainly attributable to 1 study26.  
There are important differences between studies that examined weight change during 
chemotherapy in breast cancer patients, which may partly explain the large variation in body 
weight changes observed between studies. First, the amount and type of chemotherapy changed 
over time, from cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in the 1970s and 
1980s, to anthracyclines in the 1990s, to more taxane-based regimens nowadays27-29. Second, 
characteristics of included patients differed between studies. Some studies investigated only 
premenopausal women, while other studies included both, pre- and postmenopausal women. 
A third important difference is the time between the body weight measurements. Some studies 
followed patients only during chemotherapy with body weight measured before and shortly after 
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chemotherapy. Other studies followed patients for a year or even longer with varying moments 
of weight measurements during follow-up. Fourth, the sample size varied substantially between 
studies, ranging from less than 10 till more than 200 participants. A fifth important difference is 
the study design: some studies retrieved body weight as reported in the medical records, while 
other studies had a prospective design with standardized measurements of body weight before, 
during and after chemotherapy.
Reviews regarding body weight gain during chemotherapy for breast cancer patients were 
narrative reviews and did not provide summary estimates for weight change so far. Therefore, 
the purpose of this meta-analysis was to quantify changes in body weight during chemotherapy 
for women with early stage breast cancer, and to assess which factors contributed to the 
heterogeneity between studies. 
 
Methods
Literature search
A comprehensive search of literature was conducted using PubMed, Scopus and Embase 
databases. Search term included:  “body weight change” , “body weight”, “breast cancer”, “breast 
neoplasm”, “breast carcinoma”, “breast tumor”, “breast tumour”, “breast adenoma”, “mamma,” 
“chemotherapy”, “chemo” and “cytostatic” (see additional file 3.1 for more details). The search was 
limited to human studies, published in English up to and including December 2015. In addition, 
references listed in papers were screened for additional papers, resulting in the inclusion of one 
additional paper.
Paper selection
Papers were included if they met the following criteria: early stage breast cancer patients treated 
with chemotherapy, type of chemotherapy reported, at least two measurements of body weight: 
one before and one after chemotherapy treatment. Both observational and intervention studies 
were included. Intervention studies were included if they included a control group receiving 
usual care; only the information of this usual care group was included in the meta-analysis. 
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One database was created and duplicate references were deleted. First, titles were screened 
on eligibility by two researchers (MB and RW). Secondly, abstracts were screened. If an abstract 
did not contain sufficient information to assess eligibility, the full-text was reviewed to assess 
eligibility. Communication letters, abstracts and poster of conferences were excluded.
Data extraction
From each relevant paper, information on first author, year of publication, country, study 
design, sample size, characteristics of study population (baseline age, baseline height, baseline 
menopausal status), breast cancer stage, type of chemotherapy, duration of chemotherapy, 
follow-up period between measurements of weight, adjuvant/neo-adjuvant chemotherapy, time 
points of weight assessment in relation to start and stop dates of chemotherapy, and weight or 
weight change (kg) with standard deviation (SD), 95% confidence interval or range were extracted 
and stored in a database. 
Quality assessment
To assess whether studies of lesser quality could have influenced the results, two researchers 
(MB and RW) independently assessed the quality of the included studies using an adapted 
version of the Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies30. 
Studies could get a maximum of 6 points, in four quality areas: 1) representativeness of the 
sample (information about number of people eligible and included); 2) loss to follow-up of 
participants (information about number lost to follow-up); 3) information about exposure (type 
of chemotherapy regimens); 4) assessment of the outcome (information how body weight was 
assessed). The rating system scores studies from 0 (low quality) to 6 points (high quality). A total 
score of 3 or less points was considered low quality, whereas a score of 4 or more points was 
considered high quality.
Statistical analysis
When no mean body weight change or SE was reported these were calculated if possible for each 
paper. When data on mean baseline weight and height were available we calculated the baseline 
mean BMI for the total group of participants using the formula: BMI= weight (kg) / height2 (m). If 
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weight or weight change was reported for different types of chemotherapy or menopausal status 
separately, these results were included instead of the overall mean weight change. Random-
effect models were used to calculate the mean and 95% confidence interval of the weight 
change during chemotherapy for breast cancer. Statistical heterogeneity between studies was 
assessed by the I2 statistic. I2 of 25%, 50% or 75% were interpreted as indicating low, moderate 
and high heterogeneity, respectively31. To investigate potential sources of heterogeneity, we 
conducted stratified analyses.  These included the factors: type of chemotherapy (CMF included 
vs no CMF included), sample size (n=<100 vs n=>100), menopausal status (premenopausal, 
postmenopausal, both), baseline mean BMI (20.0-24.9 vs 25.0-29.9), study design (prospective 
vs chart review), second measurement of body weight (the end of chemotherapy / 6 months 
after baseline’ group vs ‘6 months after chemotherapy / 12 months after baseline’ group),  year 
of publication (before and including 2000 vs after 2000), country (US, Canada, Western Europe, 
Australia, Turkey, Korean) and study quality (low quality vs high quality) . Of all factors included in 
the stratified analysis with data available of all estimates we conducted meta-regression analyses. 
We included the factors that were statistically significant in the univariate stratified analyses in a 
multivariate regression analysis. Regression coefficients, 95% confidence intervals and p values 
were reported. Sensitivity analyses were conducted by excluding one study at a time to explore 
whether one study markedly affected the results or highly contributed to the heterogeneity. A 
second  sensitivity analysis was conducted by excluding the only intervention study included. 
Finally, sensitivity analyses were done excluding studies included < 50 participants, and excluding 
studies included >200 participants to explore whether the smallest or largest studies markedly 
affect the results.  Statistical analyses were conducted using STATA version 11 (StataCorp, 
College Station, TX). A p-value < 0.05 was considered statistically significant.
 
Results
The results of the literature search and study selection are summarized in Figure 3.1. In total 
the database searches yielded 2,445 references. After duplicates were deleted 2,022 titles and 
138 abstracts were screened for eligibility. A total of 52 full texts were screened, of which 27 
papers were excluded, resulting in 25 eligible papers. Papers were excluded for the following 
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reasons: full-text could not be obtained (n=2); articles did not report a weight change (n=4); 
articles included a variety of cancer types and did not report results for breast cancer separately 
(n=3); articles did not report weight changes during chemotherapy (n=3); weight change was not 
reported in kg, but only as percentage change (n=4); type of chemotherapy was not reported 
(n=4); chemotherapy was combined with other treatment e.g. radiotherapy (n=4); only an 
intervention group (n=2). One paper was excluded because a more recent paper about the 
same study was published. In total, 34 weight change estimates from 25 papers were included 
in this meta-analysis. Six papers reported results for weight gain in subgroups receiving different 
kind of chemotherapy treatments.
 
Figure 3.1. Paper screening and data extraction progress
Pub Med
n=907
Embase
n=631
Duplicates n=423
Abstracts n=86
No abstract n=16
Intervention study n=7
Not available n=3
No chemothrapy n-2
No weight change n=46
Review n=12
Titles n=1884
Conference n=8
No chemothrapy n=181
No weight change n=75
No early stage n=192
No treatment n=437
No breast cancer n=411
No English paper n=32
No human studies n=548
Full text n=27
No type of chemothrapy n=4
No amount of weight change n=4
Other cancer n=3
Other treatment n=4
Not available n=2
No weight change n=4
Only trial n=2
More recent n=1
n=25
Scopus
n=907
n=2445
n=2022
n=138
n=52
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Characteristics of the participants and study designs
Characteristics of the studies included in this meta-analysis are shown in Table 3.1. The 25 
papers were published between 1985 and the end of 2015. Thirteen weight change estimates 
were published up to and including 2000 17,32-38 , and 21 after 2000 1,6-8,12,18-20,39-47.  In total, 20 
weight change estimates included patients treated with CMF. Sixteen weight estimates retrieved 
body weight from medical chart review. Eighteen had a prospective design of which one body 
weight estimate was an intervention study. Sample size of the body weight estimates varied from 
8 to 483 participants. All papers used body weight before start of chemotherapy as baseline 
measure. For the second time point of measurement we created two groups: 1) ‘the end of 
chemotherapy / 6 months after baseline’ group and 2) ‘the 6 months after chemotherapy / 
12 months after baseline’ group. The first group contained studies for which the second 
measurement was either directly after chemotherapy or 6 months after diagnosis, the second 
group all studies for which the second measurement was 6 months after chemotherapy or 12 
months after diagnosis.  
Overall, data from 2620 women were included in this meta-analysis.  The mean age of the 
study samples ranged from 39-56 years. Most papers included a combination of pre- and 
postmenopausal women. Seven papers included only premenopausal women. Two papers 
showed results separately for pre- and postmenopausal women. Table 3.2 gives an overview of 
the quality assessment of the studies included in this meta-analysis. 8 papers scored a total of 3 
or less points for study quality and were assessed as low quality studies.
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Table 3.2. Summary of the quality assessment of included studies using an adapted version of the 
Newcastle-Ottawa scale for assessing the quality of nonrandomised studies.
First author,  Representativeness Loss to follow-up  Information Measurement   
year of of sample  of participants about exposure of outcome Total
publication  (2 points) (1 point) (1 point) (2 point)s score
Foltz,1985 2 1 1 1 5/6
Heasman, 1985 2 1 1 1 5/6
Huntington, 1985 1 0 1 1 3/6
Goodwin ,1988 2 1 1 1 5/6
Demark-Wahnefried, 1997 1 1 0 1 3/6
Aslani, 1999 1 1 1 1 4/6
Goodwin, 1999 1 1 0 2 4/6
Kutynec , 1999 2 1 1 1 5/6
Demark-Wahnefried, 2001 2 1 0 2 5/6
McInnes, 2001 1 1 0 1 3/6
Del Rio, 2002 1 1 1 0 3/6
Lankester, 2002 1 1 0 1 3/6
Freedman, 2004 1 1 0 2 4/6
Harvie, 2004 1 1 0 2 4/6
Ingram, 2004 2 1 1 2 6/6
Kumar, 2004 2 1 0 1 4/6
Campbell, 2007 1 1 0 2 4/6
Courneya, 2007 2 1 0 1 4/6
Makari-Judson, 2007 2 1 0 1 4/6
Heideman, 2009 2 1 0 1 4/6
Biglia, 2010 1 1 0 0 2/6
Tredan, 2010 1 1 0 1 3/6
Basaran, 2011 1 0 0 1 2/6
Jeon, 2014 1 1 1 1 4/6
Winkels, 2014 2 1 1 1 5/6
(1) Representativeness of sample (2 points: extensive information on number of people eligible and included, 1 point: 
extensive information about recruitment, but not about number of people eligible and included, 0 points: only brief 
information about recruitment. 
(2) Loss to follow-up of participants (1 point: information about number lost to follow-up; 0 points: no information about 
number lost to follow-up). 
(3) information about exposure (1 point: results are given separate for different chemotherapy regimens, 0 points: results 
are not separated out for chemotherapy regimens). 
(4) assessment of the outcome (2 points: measurement protocol for body weight, 1 point: body weight information for chart 
review or measurement without protocol, 0 points: no information on how body weight was assessed). 
The rating system scores studies from 0 (low quality) to 6 points (high quality).
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Overall estimate
Mean weight change reported in the papers ranged from -0.8 to 7.7 kg. A gain in body weight 
was reported in 31 of the 34 estimates, figure 3.2. The pooled mean weight change was 2.7 kg 
(95%CI: 2.0-3.3) with a heterogeneity of 94.2%. To further explore this high heterogeneity, 
stratified analyses were conducted.
Figure 3.2. Weight change during chemotherapy for early stage breast cancer. Mean weight changes in 
individual estimates are depicted as squares with 95% confidence intervals (CI). Pooled estimates with 
95%CI are depicted as open diamonds.
I−V Overall  (I−squared = 94.2%, p = 0.000)
Demark−Wahnefried, 2001
Heasman, 1985
Winkels, 2014
Heideman, 2009
Goodwin, 1999
Heasman, 1985
Biglia, 2010
Study
Kutynec, 1999
Tredan, 2011
Ingram,2004
Goodwin, 1988
Jeon, 2014
McInnes, 2001
Huntington, 1985
Del Rio, 2002
Heideman, 2009
Kunmar, 2004
Ingram,2004
Harvie, 2004
Courneya, 2007
Campbell, 2007
Huntington, 1985
Tredan, 2012
ID
Basaran, 2011
D+L Overal l
Demark−Wahnefried, 1997
Makari−Judson, 2007
Aslani, 1999
Ingram,2004
Lankester, 2002
Freedman, 2004
Heasman, 1985
Huntington, 1985
Goodwin, 1988
Foltz, 1985
3.17 (3.04, 3.30)
2.20 (1.47, 2.93)
2.72 (2.07, 3.37)
1.20 (0.71, 1.69)
2.20 (−1.86, 6.26)
2.50 (1.79, 3.21)
3.65 (3.02, 4.28)
2.07 (1.19, 2.95)
0.00 (−5.59, 5.59)
1.20 (0.59, 1.81)
1.00 (0.33, 1.67)
2.51 (2.04, 2.98)
3.64 (−3.61, 10.89)
3.40 (2.75, 4.05)
4.76 (4.52, 5.00)
2.80 (1.70, 3.90)
2.60 (−0.71, 5.91)
0.40 (−1.81, 2.61)
5.00 (1.47, 8.53)
3.30 (1.30, 5.30)
1.20 (−2.15, 4.55)
1.98 (−7.94, 11.90)
2.63 (1.22, 4.04)
0.20 (−0.45, 0.85)
ES (95% CI)
1.70 (−0.14, 3.54)
2.65 (1.99, 3.32)
0.00 (−6.82, 6.82)
2.60 (1.48, 3.72)
2.35 (1.13, 3.57)
1.50 (−0.01, 3.01)
3.68 (2.90, 4.46)
−0.83 (−2.42, 0.76)
6.20 (5.42, 6.98)
7.67 (5.93, 9.41)
5.55 (4.33, 6.77)
2.99 (−2.60, 8.58)
100.00
3.41
4.29
7.47
0.11
3.60
4.56
2.31
Weight
0.06
4.86
4.04
8.11
0.03
4.29
32.44
1.49
0.16
0.37
0.14
0.45
0.16
0.02
0.90
4.29
(I−V)
0.53
0.04
1.44
1.22
0.79
2.92
0.71
2.92
0.59
1.22
0.06
%
  
0−10 10
 3
Ch
ap
te
r 3
  |
   
 W
ei
gh
t c
ha
ng
e 
du
rin
g 
ch
em
ot
he
ra
py
 in
 b
re
as
t c
an
ce
r p
at
ie
nt
s:
 A
 m
et
a-
an
al
ys
is
48
Stratified and sensitivity analyses
Body weight change estimates were stratified by type of chemotherapy, sample size, menopausal 
status, baseline BMI, study design, time between body weight measurements, year of publication, 
country, and study quality see table 3.3. Overall, weight gain was observed in all strata. Stratified 
analyses did not substantially reduce heterogeneity. The high heterogeneity remained for most 
subgroups except for the body weight change estimates in studies with a normal mean BMI at 
baseline (I2=45.1%) who had a low heterogeneity and estimates not including CMF (I2=74.7%), 
including studies with a mean BMI >25 at baseline (I2=73.2%), and for prospective studies 
(I2=69.5%), which all showed a moderate heterogeneity.
Sensitivity analyses excluding one study at a time did not markedly influence the overall result of 
weight change (range 2.4-2.8 kg) nor did importantly affect the amount of heterogeneity (range 
I2 89.2-94.6%), neither did excluding the smallest or largest studies. In addition, excluding the 
intervention study did also not markedly influence the overall result of weight change 2.7 kg 
(95%CI: 2.0-3.4)42. 
Of the 21 body weight change estimates from studies published after 2000, 10 estimates included 
women treated with CMF. The main weight change in the body weight change estimates from 
studies after 2000 including women treated with CMF was 2.8kg (95%CI: 2.0, 3.5) compared to 
1.0kg (95%CI: 0.5, 1.5) in those that did not include women treated with CMF. 
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Table 3.3. Stratified pooled mean weight change and 95% confidence interval in women during 
chemotherapy treatment for early stage breast cancer.
a  Confidence interval 
b I2= the percentage heterogeneity due to between-study variation
Table 3.3. Stratified pooled mean weight change and 95% confidence interval in women during chemotherapy 
treatment for early stage breast cancer. 
 No of 
estimates 
Pooled 
weight 
change kg 
95% CI a I2 b 
Overall 
All 
 
34 
 
2.7 
 
2.0, 7.5 
 
94.2 
Type Chemotherapy 
CMF included 
No CMF 
 
20 
14 
 
3.5 
1.4 
 
2.7, 4.3 
0.7, 2.0 
 
93.7 
74.7 
Menopausal status 
Premenopausal 
Postmenopausal 
Perimenopausal 
Combination 
 
9 
2 
1 
22 
 
2.6 
1.3 
4.8 
2.7 
 
1.5, 3.6 
-1.1, 3.7 
4.5, 5.0 
2.0, 3.4 
 
86.9 
89.4 
 
88.3 
Baseline mean BMI 
20.0-24.9  
25.0-29.9 
Unknown 
 
6 
15 
13 
 
0.5 
2.4 
3.5 
 
-0.4 ; 1.3 
1.8 ; 3.6 
2.6 ; 4.5 
 
45.1 
73.2 
95.4 
Follow-up 
end of chemotherapy /  
6 months after baseline 
6 months after chemotherapy /  
12 months after baseline 
 
26 
 
8 
 
 
2.7 
 
2.4 
 
 
2.0; 3.5 
 
1.3; 3.4 
 
 
93.8 
 
90.9 
Type of study 
Chart review 
Prospective 
 
16 
18 
 
3.6 
1.6 
 
2.8, 4.4 
1.1, 2.2 
 
94.8 
69.5 
Publication year 
Before and including 2000 
After 2000 
 
13 
21 
 
3.8 
1.9 
 
2.9, 4.7 
1.3, 2.5 
 
93.3 
81.6 
Sample Size 
≤100 
>100 
 
23 
11 
 
3.0 
2.1 
 
2.2, 3.9 
1.3, 2.8 
 
92.7 
90.1 
Country 
United States 
Canada 
Western Europe 
Australia 
Turkey 
Korea 
 
10 
12 
9 
1 
1 
1 
 
2.8 
3.1 
2.0 
2.4 
1.7 
3.6 
 
1.6 ; 4.1 
2.1 ; 4.1 
1.1 ; 2.8 
1.1 ;3.6 
-0.1 ; 3.5 
-3.6 ; 10.9 
 
93.4 
91.8 
86.2 
Study quality 
Low quality 
High quality 
 
11 
23 
 
2.9 
2.5 
 
1.6 ; 4.1 
1.8 ; 3.2 
 
96.7 
88.8 
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Meta-regression analysis 
Results of the meta-regression analyses are shown in table 3.4. Results of the univariate model 
showed that weight gain was significantly different for body weight estimates from studies 
including CMF vs estimates from studies not including CMF,  for studies using chart review vs 
prospective studies, and for studies published before 2000 vs studies published after 2000. In 
the multivariate model, we studied the combined effect of type of chemotherapy, study design 
and year of publication. In this model type of chemotherapy and year of publication remained 
significantly associated with body weight change, although the body weight change estimates 
were attenuated. Study design was no longer statistically significantly associated with body 
weight change in the multivariate model. The residual I2 for the multivariable regression model 
was 84.8%, indicating that these factors explained only a small part of the heterogeneity. 
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Table 3.4. Results from multivariate meta-regression analysis on weight change in subgroups of early 
stage breast cancer patients during chemotherapy
a  Regression coefficient  
s  Standard error 
c  Confidence interval 
d  Adjusted for, type of chemotherapy, type of study and publication year
Table 3.4. Results from multivariate meta-regression analysis on weight change in 
subgroups of early stage breast cancer patients during chemotherapy 
 Unadjusted Adjustedd 
 RCa SEb 95% CIc P-
value 
RCa SEb 95% CIc P-
value 
Type chemotherapy 
No CMF  
CMF included 
 
ref 
2.2 
 
 
0.6 
 
 
1.1, 3.3 
 
 
<0.01 
 
ref 
1.4 
 
 
0.6 
 
 
0.3, 2.6 
 
 
0.02 
Menopausal status 
Premenopausal 
Postmenopausal 
Perimenopausal 
Combination 
 
ref 
-1.3 
2.2 
0.1 
 
 
1.4 
1.8 
0.8 
 
 
-4.1, 1.5 
-1.5, 5.8 
-1.5, 1.6 
 
 
0.36 
0.23 
0.91 
    
Follow-up 
end of chemotherapy /  
6 months after baseline 
6 months after 
chemotherapy /    
12 months after 
baseline 
 
ref 
 
 
-0.1 
 
 
 
 
 
0.1 
 
 
 
 
-0.3 ; 0.2 
 
 
 
 
0.64 
 
Type of study 
Chart review 
Prospective 
 
ref 
-2.0 
 
 
0.6 
 
 
-3.1, -0.8 
 
 
<0.01 
 
ref 
-0.7 
 
 
0.6 
 
 
-1.9, 0.5 
 
 
0.24 
Publication year 
After 2000 
Before and including 
2000 
 
ref 
1.9 
 
 
0.6 
 
 
0.8, 3.1 
 
 
<0.01 
 
ref 
1.3 
 
 
0.5 
 
 
0.2, 2.3 
 
 
0.02 
Sample Size 
≤100 
>100 
 
ref 
-1.0 
 
 
0.7 
 
 
-2.3, 0.4 
 
 
0.15 
Country 
United States 
Canada 
Western Europe 
Australia 
Turkey 
Korea 
 
ref 
-0.2 
-0.8 
-0.5 
-1.1 
0.8 
 
 
0.9 
0.9 
1.9 
2.1 
4.1 
 
 
-1.5 ; 2.0 
-2.6 ; 1.0 
-4.5 ; 3.5 
-5.4 ; 3.1 
-7.7 ; 9.3 
 
 
0.79 
0.39 
0.80 
0.58 
0.85 
Quality assessment 
Low Quality 
High Quality 
 
ref 
-0.4 
 
 
0.7 
 
 
-1.8 ; 1.0 
 
 
0.58 
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Discussion
The present work is the first meta-analysis that quantified changes in body weight during 
chemotherapy in women with early stage breast cancer. Based on 25 papers, a mean weight gain 
of 2.7 kg (95%CI: 2.0-3.3) was observed with a heterogeneity of 94.2%. Stratified analysis showed 
weight gain in all strata, but the strata could only marginally explain the heterogeneity. Adjusted 
weight gain estimates based on body weight estimates from studies including patients treated 
with CMF and papers published before 2000 were larger compared to estimates from studies in 
which CMF was not included and papers published after 2000. Despite the high heterogeneity 
which could only partly be explained, the results of this meta-analysis suggest constant and 
significant weight gain during chemotherapy for women with early stage breast cancer.  
Treatment for breast cancer has changed over time. Before the 1990s, only CMF was used as 
chemotherapy regime, while during the 90s the use of anthracyclines gradually increased. In 
studies after 2004, taxane-based chemotherapy was introduced as a treatment for early stage 
breast cancer. In the current meta-analysis, CMF emerged as a chemotherapy associated with 
weight gain, which use has importantly decreased over time. However, our meta-analyses also 
showed that in studies published after the year 2000 the mean weight gain was still considerable 
1.3 kg. Stratified by type of chemotherapy, the mean weight change from studies published 
after 2000 and including women treated with CMF was 2.8 kg compared to 1.0 kg in those 
that did not include women treated with CMF. These data suggest that the abandoning of CMF 
as the chemotherapeutic regimen of choice could be an important reason for observing less 
weight gain in more recent studies. Independently of CMF, time of publication was associated 
with weight gain. A possible reason why studies after 2000 observed less weight gain relative 
to earlier studies could be the incremental use of taxanes in more recent years. However, as 
the studies included in this meta-analysis did not all provide detailed information on type of 
chemotherapy, we can only speculate on that.
Another possible explanation for differences in weight gain between older and more recent 
studies could be age and BMI at baseline. However, we  did not see a difference in baseline age 
and mean BMI comparing older and more recent studies. Yet, since most studies included in 
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this meta-analysis did not provide detailed information and stratified results on baseline BMI, we 
could not explore this in detail.
Weight gain appeared to be less in prospective studies than in chart review studies in our 
meta-analysis. A possible explanation for this finding is, that in prospective studies, data usually 
were collected as part of a cohort or other observational study. These studies could potentially 
include a selected (e.g. high SES) population, which make them less generalizable to the general 
population. Chart review papers usually included all patients treated with chemotherapy in a 
retrospective period of time, but completeness of data was not clearly reported in all studies. 
Thus both, chart reviews and prospective studies may suffer from incomplete data and 
selection issues, but as studies did not provide detailed information on response rates and 
possible selection, we could not explore this further in our meta-analysis. Moreover, stratified 
results on study quality did not show any differences between studies considered as low quality 
compared to studies considered of high quality, neither did stratifying on study quality reduce 
heterogeneity.
An earlier narrative review suggested that women with a normal BMI at baseline were more 
likely to gain weight compared to women who were overweight at diagnosis15, however other 
studies did not confirm this37,44. Since only one study included in this meta-analysis reported 
results for weight change stratified in categories of baseline BMI, we could not study this in 
great detail. Nevertheless, our analyses suggested a lower weight gain in studies with a mean 
normal BMI at baseline compared to studies with mean BMI > 25 at baseline. These results 
should be interpreted carefully, since they represents mean BMI for the total study, which does 
not mean that all women in that study fall within that BMI category. If the mean BMI of a study 
population is lower, other possible confounding factors may also differ from studies in which 
mean BMI is higher. However, as this is speculative, and data on other confounding factors is 
limited, we could not study this further. An important factor in the interpretation of our results 
is that heterogeneity of our estimates remained high despite elaborate analyses to explore 
possible sources of heterogeneity, including stratification and meta-regression. This high 
heterogeneity suggests that other, less studied factors may importantly contribute to weight 
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gain during chemotherapy. A factor that could contribute is ovarian failure which is especially 
relevant for premenopausal women. This ovarian failure impacts hormonal levels,  which may 
possibly be related to subsequent weight gain. Nevertheless, in the current meta-analyses we 
did not observe differences in weight gain between pre- and postmenopausal women, possibly 
because only a small part of the studies stratified for menopausal status48. Weight gain may also 
be explained by common side-effects of chemotherapy such as fatigue, potentially reducing 
habitual physical activity17,49. Recently, special programs are implemented in breast cancer 
care in various countries stimulating physical activity. These added interventions may explain 
differences between older and more recent studies. Also, chemotherapy may induce changes in 
taste and smell possibly leading to changes in dietary eating patterns which could influence body 
weight50. However, little research has focused on these sensory effects. Furthermore, reductions 
in energy expenditure in rest have been reported during and after chemotherapy which may 
lead to an increase in body weight15,51. As most studies did not publish on these potential factors, 
we could not explore whether they were possible sources of heterogeneity in our meta-analysis.
A limitation of our study is that we could not explore duration of chemotherapy as a source 
of heterogeneity. Chemotherapy duration has decreased nowadays. Literature suggest that 
duration of chemotherapy could be an important factor to weight gain15,17,51. In this meta-
analyse it was not possible to explore this  since most studies did not report the duration of 
chemotherapy. 
Another limitation is that we used the year that the manuscript was published and not the years 
the participants were enrolled into the study: time between conducting the study and publishing 
the results may vary between studies. Although year of enrolment would have been preferable, 
for 13 estimates this information was available. A sensitivity analysis using only the 21 estimates 
that had this information available showed a comparable trend of a decrease in weight gain for 
more recent studies (data not shown). 
Also we could only study changes in weight, but not in fat or fat-free mass. Future studies should 
provide more detailed information on body weight trajectories and preferably body composition, 
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as changes in fat and lean mass may be more clinically relevant. In addition, future studies 
should also report percentage of women with a significant weight loss, gain or maintenance 
rather than only mean weight change, so it is possible to establish the clinical magnitude of 
changes in body weight during chemotherapy. 
A strength of this study is that it is, to the best of our knowledge, the first meta-analysis 
conducted on weight gain in breast cancer women during chemotherapy. A comprehensive 
literature search was conducted including an additional hand search. This makes the potential 
of missing any published data in English unlikely.
In conclusion, our results indicate that women generally gain weight during chemotherapy for 
early stage breast cancer. This weight gain is more pronounced in women treated with CMF 
and is greater in studies published before 2000. Although weight gain after chemotherapy has 
decreased over the course of time, weight gain is still substantial and deserves clinical attention.
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Additional file 3.1. Search Strategy
PUBMED
Weight changes
Body weight change [mesh] OR body weight changes [mesh] OR body weight [tiab] OR weight* 
[tiab]
Breast cancer
breast cancer [mesh] OR breast cancer [tiab] OR malign* [tiab] OR neoplasm* [tiab] OR 
carcinoma* [tiab] OR cancer* [tiab] OR tumor* [tiab] OR tumour* [tiab] AND breast* [tiab] or 
mamma* [tiab]
Chemotherapy
chemotherapy [mesh] OR chemo* [tiab] OR cytostatic [mesh] OR cytostatic* [tiab]
SCOPUS
Weight change
( TITLE-ABS-KEY ( body  weight  change* )  OR  TITLE-ABS-KEY ( body  weight* )  OR  TITLE-ABS-
KEY ( weight  change* ) ) 
Breast caner
( ( TITLE-ABS-KEY ( malign* )  OR  TITLE-ABS-KEY ( neoplasm* )  OR  TITLE-ABS-KEY ( carcinoma* 
)  OR  TITLE-ABS-KEY ( cancer* )  OR  TITLE-ABS-KEY ( tumor* )  OR  TITLE-ABS-KEY ( tumour* ) ) ) 
AND  ( ( TITLE-ABS-KEY ( breast* )  OR  TITLE-ABS-KEY ( mamma* ) ) ) 
Chemotherapy
(TITLE-ABS-KEY (chemo*) OR TITLE-ABS-KEY (cytostatic*)) 
EMBASE
Weight change
Exp ‘body weight change’/ OR body weight changes. ti,ab OR body weight change*. ti,ab OR body 
weight. ti,ab
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Breast cancer
exp ‘breast cancer’/ OR breast cancer. ti,ab OR malign*. ti,ab OR neoplasm*. ti,ab   OR carcinoma*. 
ti,ab OR cancer*. ti,ab OR tumor*. ti,ab OR tumour*. ti,ab AND breast*. ti,ab OR mamma*. 
Chemotherapy
exp ‘chemotherapy/ OR chemo*. ti,ab OR exp cytostatics/ OR cytostatic*. ti,ab
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Chapter 4
Changes in body weight and 
body composition during and 
after chemotherapy in women 
with breast cancer compared to 
women without cancer
M.M.G.A. van den Berg, 
M. Visser, 
J.H.M. de Vries, 
E. Kampman, 
R.M. Winkels.
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Abstract
Background: Several studies suggested that body weight and body composition change during 
chemotherapy for breast cancer, with an increase in fat mass and a loss or no change in lean 
body mass. However, many of these studies did not include a comparison group and could not 
assess whether these changes differ from natural age-related changes in body weight and body 
composition. 
Aim: To describe the extent and patterns of changes in body weight and body composition 
in breast cancer patients during chemotherapy and 6 months after chemotherapy compared 
to age-matched women without cancer. In addition, we identified which determinants were 
associated with the changes in body weight and body composition.
Methods: We recruited 145 newly diagnosed breast cancer patients (stage I-IIIB) and 121 
women without cancer of a similar age (range +/- 2 years). Body composition was assessed 
using a Dual Energy X-ray Absorptiometry (DEXA)-scan before start of chemotherapy, shortly 
after chemotherapy, and 6 months after chemotherapy within the patient group and at three 
time points six months apart within the comparison group. 
Results: Shortly after chemotherapy, patients had a significantly higher body weight, BMI and 
lean body mass than women in the comparison group, while fat mass was similar. Six months 
after chemotherapy no differences in body weight, BMI, fat mass and lean body mass were 
observed between the patient and comparison group. In multivariate analyses, a younger 
age, better appetite during chemotherapy, and negative ER-receptor status of the tumor were 
associated with greater changes in body weight over time in the patients. A younger age and 
better appetite during chemotherapy were also associated with greater changes in fat mass 
over time, while only a better appetite was associated with greater changes in lean body mass 
over time. 
Conclusions: This study showed that in the period from start of chemotherapy until 6 months 
after the end of chemotherapy changes in body weight and body composition were minimal in 
women with breast cancer, and did not differ from natural changes over time in women of a 
similar age without breast cancer.
465
Introduction
Several reviews described that women with breast cancer gain weight during chemotherapy1-7. 
Our recent meta-analysis showed that women with breast cancer gain 2.7 kg body weight during 
chemotherapy8. Additionally, the meta-analysis suggested that weight gain was most pronounced 
in patients receiving cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimes –regimes 
that are currently being used less often- and that weight gain was less pronounced in patients 
treated with more recent types of chemotherapy8. 
To date it is unknown which factors contribute to weight gain during chemotherapy. Suggested 
factors described are treatment-induced ovarian failure accompanied by the rapid onset 
of menopause9 as well as reductions in physical activity3,5,10-12. Other factors suggested to 
be associated with weight change during chemotherapy include, premenopausal status at 
diagnosis1,3,13,14, younger age at diagnosis1,10,15 a normal BMI before start of chemotherapy1,16, 
and a high BMI and higher fat mass before start of chemotherapy17. Also changes in resting 
energy expenditure6,12,18,19 and dietary intake5,6,18,19 are described as possible factors associated 
with changes in body weight and body composition. 
Besides body weight gain, changes in body composition during chemotherapy have been 
reported, consisting of an increase in fat mass with a loss or no change in lean body mass, even 
in weight stable patients1-4,20. Changes in body weight and body composition are important, since 
it is suggested that these changes are associated with recurrence and mortality, however, not all 
studies show consistent results21-23. 
Earlier studies that investigated changes in body composition during chemotherapy in 
breast cancer patients mostly included a small study sample of 8 to 76 patients5,12,13,16,17,24-31. 
More importantly, most of these studies did not compare the changes in body weight and 
body composition in breast cancer patients to a comparison group of women without 
cancer5,12,13,16,17,24-27,29-31. The only study that included a comparison group concluded that women 
with breast cancer did not significant change in body weight during the first year of their 
treatment in comparison to the comparison group. However, patients underwent unfavourable 
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changes in body composition, with an increase in fat mass and decrease in fat-free mass and 
lean soft tissue28.Therefore, based on current literature, it is still unclear whether changes in 
body weight and composition in breast cancer patients are indeed treatment related or due to 
natural fluctuations over time.
The objective of this study was to describe the extent and patterns of changes in body weight 
and body composition in breast cancer patients (stage I-IIIB) from start of chemotherapy until 6 
months after chemotherapy compared to an age-matched comparison group without cancer. 
In addition, we investigated potential determinants of these changes in body weight and body 
composition in breast cancer patients.  
Materials and Methods
Study population
The analyses were done using data of the COBRA-study, an observational multi-centre study 
which compares women with breast cancer treated with chemotherapy with women without 
cancer who are of similar age (range +/- 2 years) 32. Women with newly diagnosed, stage I-IIIB, 
operable breast cancer, who were scheduled for 2nd or 3rd generation neo- adjuvant chemotherapy 
were included. Eligible patients were recruited via the staff of 11 participating hospitals in the 
Netherlands prior to commencement of chemotherapy. Participants in the comparison group 
were recruited via patients; patients were asked to distribute envelopes with study information 
to friends, acquaintances and colleagues. Women without cancer interested in participating in 
the study contacted the researchers and were consented for participating by the researchers. 
All study participants needed to be at least 18 years old and able to communicate in Dutch. 
Exclusion criteria for both groups were: history of cancer, previous treatment with chemotherapy, 
(intended) pregnancy, dementia or other mental conditions that made it impossible to comply 
with the study procedures. 
For the current study, we included 145 breast cancer patients and 121 women without cancer 
of the COBRA-study recruited between May 01, 2013 and December 31, 2015. 
467
The protocol was approved by the Medical Ethical Committee of Wageningen University. All 
participants provided written informed consent before enrolment. 
Study design
Measurements took place at three time points during the study period for all participants. For 
the patient group, these time points were: before start of chemotherapy or during the first 
cycle of chemotherapy (T1), shortly after chemotherapy (T2), and 6 months after chemotherapy 
(T3). For the comparison group these measurements were conducted over a similar timeframe: 
baseline (T1), 6 months after baseline (T2), and 12 months after baseline (T3).  
Measurements
Body weight and body composition
Body weight and body composition were assessed using a Dual-Energy X-ray Absorptiometry 
(DEXA)-scan at all three time points. Participants were measured 3 times in the same 
hospital using the same scanner by trained technicians using a total body scan protocol. 
From the total body DEXA-scan, body weight (kg), total body fat mass (kg), and total lean body 
mass (kg) were obtained. In addition, lean body mass (kg) of the arms, legs, and torso were 
obtained. In 60 participants body weight was also measured using a calibrated scale on all 
three time points.
Physical activity
Information regarding physical activity was derived from the validated Short Questionnaire 
to ASess Health enhancing physical activity (SQUASH) at all three time points33,34. In this 
questionnaire, participants were asked to report their average time (days per week, hours and 
minutes per day) spent in walking, cycling, gardening, odd-jobs, sport, household activities and 
work. Based on the self-reported intensity level of each activity a metabolic equivalent (MET) 
value was assigned35. According to the Dutch physical activity guideline, 4.0 MET was used as a 
lower cut off for moderate activity for those aged <55 y. For older women a lower cut off of 3.5 
MET was used36. These values were presented as MET-hours per week.
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Dietary intake
A food frequency questionnaire (FFQ) was used to assess habitual intake at baseline (T1)37,38. 
In addition, in patients we assessed scores on eating styles (restrained, emotional, external) 
using the Dutch Eating Behaviour Questionnaire (DEBQ)39. Based on these scores, patients were 
categorized in high versus low groups for each eating style.
Appetite, taste, smell, and symptoms during chemotherapy
In patients only appetite, taste, and smell during chemotherapy were assessed using the 
Appetite, Hunger feelings and Sensory Perception (AHSP) questionnaire40. A higher score on 
appetite, taste or smell corresponds with a more positive judgement about current appetite, 
taste, or smell. 
The presence of the following symptoms were assessed two times during chemotherapy: 
pain; dry mouth; feeling depressed; thick saliva; diarrhoea; sore mouth; lack of energy; nausea; 
difficulty chewing; difficulty swallowing; anxiety; constipation and vomiting. For each symptom 
the question was asked: ‘How often have you experienced this symptom during the past three 
days?’, scored on a 5 point Likert scale, ranging from 1=“not at all” to 5=“a lot”. If a symptom scored 
1 this symptom was absent while a score of 2 to 5 was coded as presence of the symptom. The 
mean score of total number of symptoms present of the two moments was calculated. A higher 
total score corresponds with more reported symptoms.
Demographic, personal and medical information
At T1 all participants filled out a questionnaire for demographic information, including body 
height, age, menopausal status, smoking status and educational level. BMI was calculated based 
on self-reported body height and body weight from DEXA-scan. Information on stage of cancer 
at diagnosis, tumour characteristics, and treatment were obtained from reviewing patients’ 
medical records using a standardized form.
469
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Data analyses
Population characteristics were described as median with an interquartile range (IQR) or number 
with percentage for the patient and comparison group separately. To assess differences in the 
characteristics between groups, the Mann-Witney U-test was used for continuous data and the 
Chi Square test for categorical data.
Differences in body weight and body composition between the patient and comparison group 
over time were analysed using Linear Mixed Models, with time, group and their interaction term 
as fixed factors and subjects as random factors in the model. 
In patients only, potential determinants of changes in body weight, body fat mass and lean body 
mass over time were assessed using Linear Mixed Models. 
Potential determinants were included in the model as an interaction term with time. We 
assessed; 1) baseline demographic and lifestyle determinants (age, education level, smoking 
status, physical activity, intake of energy, protein, carbohydrate, fat and alcohol, and eating style); 
2) clinical determinants (stage, adjuvant vs neo-adjuvant treatment, type of chemotherapy, 
receptor status, hormone treatment); 3) determinants during chemotherapy (baseline 
measurements before/during chemotherapy, appetite, taste, smell, and number of symptoms). 
Significant determinants were subsequently included in a multivariate model.
Linear Mixed Models estimated means and standard errors, presented as mean ± SE. In all 
models, a random intercept and slope model was used with appropriate covariates and 
covariance structure. Using a top-down model fitting procedure, the appropriate covariates and 
covariance structure were chosen. These differed between the various outcome variables.
In 60 participants we measured body weight using a scale and DEXA-scan, at all three time 
points. As an additional analysis, we compared whether changes in body weight over time 
differed between these two methods, using an independent T-test.
In all analyses, a p-value <0.05 was considered significant. Statistical analyses were performed in 
SAS 9.4 (SAS Institute, Cary NC).
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Results
Population characteristics
At baseline (T1), the patient and comparison group were similar in age, smoking status, physical 
activity, dietary intake, and menopausal status, while there were significantly more high educated 
women in the comparison group than in the patient group, see table 4.1. Women in the patient 
group had a significantly higher BMI, total lean body mass (kg), fat mass in the arms (kg), and fat 
mass in the legs (kg) compared to women in the comparison group. Shortly after chemotherapy 
and 6 months after chemotherapy women with breast cancer reported a significantly lower 
physical activity than women without cancer in the same time period.
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Table 4.1. Demographic and body composition characteristics of  breast cancer patients and the 
comparison group of women without cancer included in the study presented as median (IQR) or n (%).
*  Indicates a significant difference between the groups at p<0.05.
Table 4.1. Demographic and body composition characteristics of  breast cancer patients and comparison 
group of women without cancer included in the study presented as median (IQR) or n (%). 
Characteristics Patient group  
(n=145) 
Comparison group 
(n=121) 
Demographics  
Age, yrs (median, IQR) 
 
51.9 (47.7 ; 59.0) 
 
52.2 (46.7 ; 62.0) 
Menopausal status (n, %) 
 Premenopausal 
 Menopausal 
 Postmenopausal 
 Missing  
 
57 (39.3) 
20 (13.8) 
66 (45.5) 
2(1.4) 
 
52 (43.0) 
10 (8.3) 
59 (48.8) 
0 
Education level (n, %)* 
 Low 
 Medium 
 High 
 Missing    
 
14 (9.7) 
49 (33.8) 
80 (52.4) 
6 (4.1) 
 
9 (7.4) 
28 (23.1) 
83 (68.6) 
1 (0.8) 
Smoking status (n, %) 
 Current 
 Former 
 Never 
 Missing 
 
25 (17.2) 
60 (41.4) 
54 (37.2) 
6 (4.1) 
 
10 (8.3) 
57 (47.1) 
53 (43.8) 
1 (0.8) 
Physical activity   
MET-H/week at baseline (median, IQR) 
MET-H/week shortly after chemotherapy /   
6 months after baseline (median, IQR)* 
MET-H/week end of study (median, IQR)* 
139.1 (82.7 ; 172.5) 
 54.2 (25.5 ; 87.7) 
 
81.4 (44.2 ; 133.6) 
136.7 (104.5 ; 183.4) 
127.8 (72.2 ; 165.3) 
 
125.6 (68.5 ; 178.9) 
Dietary intake   
Energy, kcal (median, IQR) 1979 (1674 ; 2333) 1966 (1670 ; 2336) 
Protein, percentage (median, IQR) 15.7 (14.0 ; 17.3) 15.2 (14.1 ; 16.8) 
Fat, percentage (median, IQR) 36.9 (33.6 ; 41.0) 36.4 (33.3 ; 40.6) 
Carbohydrates, percentage (median, IQR) 42.1 (38.3 ; 45.5) 41.5 (38.2 ; 44.9) 
Alcohol, percentage (median, IQR) 1.1 (0.0 ; 3.6)) 2.3 (0.6 ; 5.0) 
Baseline body composition    
Height cm (median, IQR) 167.0 (163.5 ; 172.5) 169.0 (165.0 ; 172.5) 
Weight kg (median, IQR) 69.9 (62.9 ; 81.0) 69.8 (62.7 ; 77.2) 
BMI kg/m2 (median, IQR)* 25.4 (22.3 ; 29.0) 24.0 (22.2 ; 26.8) 
Total fat mass kg (median, IQR) 25.6 (20.0 ; 32.5) 24.2 (19.4 ; 29.8) 
Total fat mass % (median, IQR) 36.4 (31.2 ; 41.8) 34.5 (30.7 ; 39.9) 
Arms fat kg (median, IQR)* 2.9 (2.3 ; 3.8) 2.7 (2.0 ; 3.4) 
Legs fat kg (median, IQR) 9.4 (8.0 ; 12.1) 8.7 (7.0 ; 10.8) 
Trunk fat kg (median IQR) 11.4 (8.5 ; 16.1) 11.4 (8.7 ; 14.5) 
Total lean mass kg (median, IQR)* 42.6 (39.2 ; 46.6) 43.9 (40.0 ; 46.2) 
Arms lean kg (median, IQR) 4.2 (3.8 ; 4.7) 4.3 (3.9 ; 4.8) 
Legs lean kg (median IQR)* 13.8 (12.8 ; 15.4) 14.3 (12.9 ; 15.5) 
Trunk lean kg (median, IQR) 22.0 (19.4 ; 23.8) 21.7 (20.1 ; 23.1) 
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Changes in body weight and body composition 
Adjusted changes in body weight and body composition over time are presented in Figure 4.1. At 
baseline (T1) there was no difference in body weight and body composition between the patient 
and comparison group. In the comparison group, no significant changes in body weight or body 
composition over time were observed.
Body weight differentially changed over time between women with breast cancer and women 
without cancer (figure 4.1a). Breast cancer patients significantly increased in body weight from 
baseline (T1) to shortly after chemotherapy (T2) (T1: 72.0 kg ± 0.13 kg, T2: 73.1 kg ± 0.23 kg). 
However, 6 months after chemotherapy (T3) body weight had decreased (72.7 kg ± 0.38 kg). 
Compared to women without cancer, women with breast cancer had a significant higher body 
weight shortly after chemotherapy (T2), but not at 6 months after chemotherapy (T3). Similar 
results were obtained for BMI (figure 4.1b). 
Fat mass did not differentially change over time between patients and women without cancer 
(figure 4.1c). From baseline (T1) to shortly after chemotherapy (T2) breast cancer patients had 
a stable fat mass. At T3, 6 months after chemotherapy, among patients fat mass slightly yet 
significantly increased compared to baseline (T1) and shortly after chemotherapy (T2) (T1: 26.1 
kg ± 0.10 kg, T2: 26.3 kg ± 0.27 kg, T3: 26.8 kg ± 0.31 kg). 
At baseline (T1) there was no difference in lean body mass between women with breast cancer 
and women without cancer. Lean body mass differentially changed over time in patient versus 
comparison group (figure 4.1d). In the patient group, lean body mass significantly increased from 
baseline (T1) to shortly after chemotherapy (T2), but returned to baseline values at 6 months 
after chemotherapy (T3) (T1: 43.5 kg ± 0.08 kg, T2: 44.4 kg ± 0.14 kg, T3: 43.5 kg ± 0. 23 kg). At 
T2 women in the patient group had a significant higher lean body mass compared to women 
without cancer but at T3 lean body mass in the patient group was not different from lean body 
mass in the comparison group.
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Changes in lean body mass of the trunk, arms and legs of the patient group showed similar 
trends as were observed in total body lean mass: an increase from baseline (T1) to shortly after 
chemotherapy (T2), and back to baseline values 6 months after chemotherapy (T3) (figure 4.2). 
There was no difference in the changes over time between the patient and comparison group.
Table 4.2 shows the results of measurements body weight using a scale and DEXA-scan. Results 
showed that DEXA-scan slightly underestimated body weight compared to scale. However more 
importantly, changes in body weight did not differ between scale and DEXA-scan measurements.
Body weight (a) and BMI (b) are adjusted for: age, education level, baseline value ,age*group, 
Fat mass (c) and lean body mass (d) are adjusted for: age, education level, BMI,  baseline value, age*group, 
*     indicates a significant differences at this time point  between the two groups at p <0.05.
**   indicates a significant difference over time in the patient group at p <0.05.
*** indicates a significant difference over time between the patient group and comparison group at         
        p<0.05
Figure 4.1. Body composition (mean ± SE) over time for the breast cancer patients and comparison 
group without cancer. T1 represents before chemo (patients) and baseline (comparison), T2 represents 
shortly after chemotherapy (patients) and after 6 months (comparison). T3 represents a half year after 
chemotherapy (patients) and after 12 months (comparison). 
a. Body weight ***
Patient
Comparison
kg
71.0
T1 T2 T3
71.5
72.0
72.5
73.5
73.0
74.0 **
b. BMI ***
Patient
Comparison
kg
/m
2
25.0
T1 T2 T3
25.5
26.0 **
*
*
*
c. Fat mass
Patient
Comparison
kg
25.5
T1 T2 T3
26.0
26.5
27.0
27.5 **
**
d. Lean body mass ***
Patient
Comparison
kg
42.0
T1 T2 T3
42.5
43.0
43.5
44.5
44.0
45.0 ** **
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Adjusted for age, education level, baseline value, age*group
*     indicates a significant differences between the two groups at p <0.05.
**   indicates a significant difference over time in the patient group at p <0.05.
*** indicates a significant difference over time between the patient group and comparison group at 
       p<0.05 
Figure 4.2. Lean body mass for the Trunk, Arms and Legs (mean ± SE) over time for the patient and 
comparison group. T1 represents before chemo (patients) and baseline (comparison), T2 represents 
shortly after chemotherapy (patients) and after 6 months (comparison). T3 represents a half year after 
chemotherapy (patients) and after 12 months (comparison). 
Table 4.2. Results of body weight measurements by scale and DEXA-scan over time presented as mean 
(SD).  Table A presents the mean body weight at different time points, while table B presents the 
changes between the different time points. T1 represents before chemotherapy (patients) and baseline 
(comparison), T2 represents shortly after chemotherapy (patients) and after 6 months (comparison), T3 
represents 6 months after chemotherapy (patients) and after 12 months (comparison).
	
A. Body weight T1 (n=60) T2 (n=60) T3 (n=60) 
Scale measurement 71.7 (11.2) 72.1 (11.6) 71.9 (12.4) 
DEXA  measurement 71.2 (11.3) 71.6 (11.5) 71.3 (12.1) 
 
B. Changes in body weight Scale measurement DEXA measurement P-value 
T1 – T2 0.5 (2.7) 0.3 (2.6) 0.82 
T1 – T3 0.3 (4.1) 0.1 (3.6) 0.82 
T2 – T3 -0.2 (3.1) -0.3 (2.8) 0.93 
 
a. Lean body mass Trunk
Patient
Comparison
kg
21.0
T1 T2 T3
215
22.0
22.5
23.0
c. Lean body mass Legs
Patient
Comparison
kg
13.0
T1 T2 T3
13.5
14.0
14.5
15.0
b. Lean body mass Arms
Patient
Comparison
kg
3.0
T1 T2 T3
3.5
4.0
4.5
5.0
**
**
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Determinants of changes in body weight, body fat mass, and lean body mass
Table 4.3 shows results of the associations between possible determinants and changes in body 
weight, fat mass, and lean body mass in breast cancer patients. In the multivariate analyses, 
a younger age, better appetite during chemotherapy and ER-receptor negative tumour were 
associated with changes in body weight. Determinants associated with changes in fat mass were 
a younger age and better appetite during chemotherapy, while only a better appetite during 
chemotherapy was associated with changes in lean body mass.
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Discussion
In our study we found that, from baseline to shortly after chemotherapy, patients experienced 
an increase in body weight, BMI and lean body mass, but not fat mass, compared to women 
without cancer. However, 6 months after chemotherapy we did no longer find a difference in 
body weight, BMI, lean body mass, and fat mass in the patient group compared to the women 
without cancer. These results suggest that the observed increases in body weight and change in 
body composition during chemotherapy in the patient group are temporary.
A second objective of our study was to identify potential determinants of the changes in body 
weight and body composition in breast cancer patients over time. Our multivariate results 
suggest that a younger age, better appetite during chemotherapy, and an ER-receptor negative 
tumour were associated with greater changes in body weight over time. A younger age and 
better appetite during chemotherapy were associated with greater changes in fat mass over 
time, while the only determinant associated with greater changes in lean body mass over time 
was a better appetite during chemotherapy.  
We found an increase in body weight in the patient group of 1.1 kg  during chemotherapy (from 
72.0 kg ± 0.13 kg at baseline (T1) to 73.1 kg ± 0.23 kg shortly after chemotherapy (T2), which is in 
line with the results of our meta-analysis were we found a mean weight gain of 1.4 kg in women 
receiving a newer chemotherapy regime8. After chemotherapy (T3), body weight decreased to 
72.7 kg ± 0.38 kg and was not longer significantly different from baseline. These findings on body 
weight are consistent with several other recent studies that also did not find substantial weight 
gain13,14,28,41. Older studies5,9,15,19,42-46 tended to find increases in body weight, possible because 
those studies included other chemotherapy regimens.
Our results suggest that lean body mass increased during chemotherapy, but decreased to 
baseline values in the 6 months after chemotherapy. This increase in lean body mass during 
chemotherapy was unexpected, especially since physical activity decreased during chemotherapy 
compared to baseline values. Therefore, it is likely that the increase in lean body mass is not a 
change in muscle mass, but a change in body fluid. The findings from Pedersen13 support this 
4Chapter 4  |    Changes in body w
eight and body com
position during and after
chem
otherapy in w
om
en w
ith breast cancer com
pared to w
om
en w
ithout cancer
79
suggestion, as they showed an increase in total body water, measured by BIA, 6 months after 
start of chemotherapy in breast cancer patients, which was normalized to baseline values after 12 
months13. A possible explanation for fluid retention could be the use of a chemotherapy regime 
including docetaxel, since it is suggested that docetaxel can cause fluid retention47. Additionally, 
dexamethasone – which is frequently prescribed during chemotherapy - can cause fluid retention. 
In our study, we could not assess use of dexamethasone as medical records only contained 
information on prescription of this drug, but not on actual use.
Fat mass in the patient group was stable during chemotherapy and slightly but significantly 
increased in the 6 months after chemotherapy. However, over the whole study period, there was 
no differential change in fat mass between the patient and comparison group. Thus, it seems 
not possible to attribute the change in fat mass to the cancer treatment. This finding highlights 
the importance of including a comparison group. Without a comparison group, it could be 
concluded that women gain fat mass after chemotherapy treatment. 
Our finding that younger age was associated with greater changes in body weight and fat mass 
are consistent with findings from others1,10,15. Other studies suggest that this may be related to 
menopausal status at diagnosis1,3,13,14. However, it is challenging to obtain reliable information 
on menopausal status48, and since we only had self-reported data on menopausal status in our 
study, we decided to include age at diagnosis in our analysis.
Body weight and body composition were assessed using a DEXA-scan; for each participant all 
measurements were performed on the same scanner. Thus, although several scanners were 
used in this study, each participant was measured three times on the same scanner in the same 
hospital. Therefore, it was possible to assess changes over time within a person, although we 
cannot exclude that the type of scanner used, influenced the observed changes. In our study, we 
used body weight as assessed with the DEXA-scan, since it turned out to be logistically impossible 
to use validated scales to assess body weight. In a subgroup of 60 participants we measured 
body weight by scale and DEXA-scan on all three time points and showed that changes in body 
weight over time were not different based on scale measurement vs based on DEXA-scans.
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In conclusion, we observed that in the period from start of chemotherapy until 6 months after 
the end of chemotherapy changes in body weight and body composition are minimal in women 
with breast cancer, and do not differ substantially from natural changes over time in women 
of a similar age without breast cancer. During chemotherapy we observed slight increases in 
body weight and body composition, however, 6 months after chemotherapy there were no 
differences between patients and women without cancer. This study does not confirm findings 
from others that fat mass and/or lean body mass change substantially during chemotherapy in 
breast cancer patients. 
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Abstract
Purpose: Breast cancer patients receiving chemotherapy often experience symptoms such as 
nausea, vomiting and loss of appetite that potentially affect dietary habits. This study assessed 
the intake of energy, macronutrients and food groups before and during chemotherapy in 
breast cancer patients compared  with women without cancer, and determined the association 
between symptoms and energy and macronutrient intake.
Methods: This study included 117 newly diagnosed breast cancer patients scheduled for 
chemotherapy and 88 women without cancer. Habitual intake before chemotherapy was 
assessed with a food frequency questionnaire. Two 24h dietary recalls were completed on 
random days for each participant during the whole chemotherapy treatment for patients and 
within 6 months after recruitment for women without cancer. Shortly after the dietary recall, 
participants filled out questionnaires on symptoms. 
Results: Before chemotherapy, habitual energy and macronutrient intake was similar for breast 
cancer patients and women without cancer. During chemotherapy, breast cancer patients 
reported a significantly lower total energy, fat, protein and alcohol intake than women without 
cancer, as shown by a lower intake of pastry and biscuits; cheese; legumes; and meat products. A 
decline in subjective taste perception, appetite, hunger, and experiencing a dry mouth, difficulty 
chewing, lack of energy and nausea were associated with a lower energy intake.  
Conclusions: Symptoms induced by chemotherapy are associated with lower dietary intake, 
and manifested by a lower intake of specific food groups. To ensure an optimal dietary intake 
during chemotherapy, it is important to monitor nutritional status and symptom burden during 
chemotherapy in breast cancer patients.
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Introduction
The majority of women with breast cancer is treated with chemotherapy1. Treatment with 
cytotoxic drugs is often accompanied with symptoms such as nausea, vomiting, loss of appetite, 
dry mouth and changes in taste or smell perception. These symptoms can be very disturbing 
and can significantly impact quality of life2,3. In types of cancer where the gastro-intestinal tract 
is affected, such as head and neck cancer, the impact of these symptoms on dietary intake and 
nutritional status is well established4,5. However, for breast cancer patients the experience of 
symptoms during cancer treatment may differ and the extent to which symptoms specifically 
affect dietary intake in breast cancer patients is less clear. 
Previous studies that investigated whether dietary intake changed during chemotherapy in breast 
cancer patients are inconsistent in their findings. They either showed increases6, decreases7,8, 
or no changes9-11 in energy intake during chemotherapy, possibly because different studies 
used different methods and different time points during the course of chemotherapy to assess 
dietary intake. Most studies in breast cancer patients assessed dietary intake only in the week 
prior to a next chemotherapy cycle, while dietary intake is suggested to vary during a cycle12. 
Most importantly, earlier studies did not compare dietary intake in breast cancer patients to a 
comparable group of women without breast cancer, limiting the possibility to assess whether 
changes in intake deviate from normal fluctuations in intake over time. Additionally, most studies 
are limited by only focussing on energy and macronutrient intake, and not on food items or food 
groups. Thereby it is unknown whether changes in dietary intake during chemotherapy are due 
to changes in intake of specific food groups. 
There are studies that suggest that breast cancer patients gain weight during and after 
chemotherapy, which may be associated with an increased risk of comorbidities like 
cardiovascular disease and diabetes13,14. Therefore it is important to give breast cancer patients 
well-grounded advice on their lifestyle and dietary habits before, during and after treatment. 
Especially since breast cancer patients have expressed a need for dietary support during 
treatment with chemotherapy15; unmet supportive care needs in cancer patients are highest 
during treatment16. However, in order to give specific dietary advice it is important to first know 
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what the actual change in dietary intake of breast cancer patients is and which symptoms are 
associated with dietary changes during chemotherapy. 
Therefore, the aim of this observational study was to assess the intake of energy, macronutrients 
and food groups before and during chemotherapy in breast cancer patients in comparison with 
a group of women without cancer, and to determine the association between the experience of 
specific symptoms and energy and macronutrient intake. 
 
Materials and Methods
Participants
This study is part of an ongoing observational multi-centre study among breast cancer patients 
during chemotherapy and a comparison group of women of similar age without cancer (COBRA-
study). Women with newly diagnosed, incident, stage I-IIIB, operable breast cancer, scheduled 
for 2nd or 3rd generation chemotherapy were compared with women without cancer of similar 
age (range within 2 years). Eligible patients were recruited by the staff of 11 participating 
hospitals prior to commencement of chemotherapy. The comparison group was recruited 
via the women with breast cancer, who were asked to distribute information about the study 
to female friends, acquaintances and colleagues. This approach was chosen to maximize the 
comparability of groups with respect to possible confounding factors, and thus to minimize the 
risk that other factors than chemotherapy influenced our findings on dietary intake. Women 
without cancer contacted the researchers if they were interested in participating in the study. 
All study participants needed to be at least 18 years old and be able to communicate in Dutch. 
Exclusion criteria were: history of cancer, previous treatment with chemotherapy, pregnancy 
or the intention to get pregnant during the study period, dementia or other mental conditions 
that made it impossible to comply with the study procedures. The protocol was approved by 
the Medical Ethical Committee of Wageningen University (ABR NL40666.081.12). All participants 
provided written informed consent before enrolment.
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Measurements 
Dietary intake
Upon recruitment, all participants filled out a food frequency questionnaire (FFQ) to assess 
habitual intake before chemotherapy (patient group) or start of the study (comparison group)17,18. 
During chemotherapy, actual dietary intake was assessed using two telephone-based 24h dietary 
recalls, because of the expected high day to day variation during chemotherapy. The recalls were 
planned on two random days during chemotherapy, during all weeks within a chemotherapy cycle 
and over all chemotherapy cycles administered. Recalls were planned between the day of the 
first chemotherapy infusion and three weeks after the last chemotherapy infusion. Women in the 
comparison group also completed two recalls, which were planned on two random days within 6 
months after recruitment. This was a comparable time-frame, as current oncological guidelines 
for chemotherapy for breast cancer in the Netherlands encompass schemes which mostly take 
4.5 to 6 months to complete. Randomization of the recall days was done for each participant 
separately. The two recalls were scheduled at least 7 days apart. If it was not possible to complete 
the recall on the scheduled day, a new day was planned randomly within 2 weeks. The 24h-recalls 
were performed using a standardized protocol and conducted by trained dietitians. The recalls 
were at least one week apart and were conducted both on week and weekend days. Dietary recall 
data were coded and entered, after which the intake of total energy, protein, carbohydrate, fat, 
alcohol and fibre were calculated in the computation module of Compl-eat™ using the Dutch food 
composition table 201319. A data check was performed by the dietitians. The highest and lowest 
ten values for energy, macronutrients, and fruit and vegetables intake were checked for errors 
in coding or amounts. Food items were grouped into food groups for both the food frequency 
questionnaire and 24h dietary recall19. These food groups were: bread; cereal and cereal products; 
fruit; vegetables; legumes; nuts, seeds and snacks; soups; soy products and vegetarian products; 
pastry and biscuits; sugar, candy sweet toppings and sweet sauces; milk and dairy products; 
cheese; eggs; meat and meat products; and fish.
Symptoms 
After being called for each 24h recall, participants were instructed to fill out questionnaires 
on sensory perception and experienced symptoms. The Appetite, Hunger feelings and Sensory 
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Perception (AHSP) questionnaire was used to assess self-judgement of taste, smell and 
appetite20. The questionnaire consisted of 29 questions answered on a 5 point Likert scale, 
concerning four categories; taste (8 items, score range 8-40), smell (6 items, range 6-30), appetite 
(6 items, range 6-30) and hunger (9 items, range 9-45). An example of a question for taste was: 
In former days the taste of food was: 1. much better than nowadays, 2. better than nowadays, 
3. the same as nowadays, 4. worse than nowadays, 5. much worse than nowadays. For the 
patient group, ‘former days’ was referenced as the situation before chemotherapy and for the 
comparison group as the situation one year ago. A higher score corresponds to a more positive 
judgement about current taste and smell perception, appetite and hunger. The severity of 13 
additional symptoms was assessed: pain; dry mouth; feeling depressed; thick saliva; diarrhoea; 
sore mouth; lack of energy; nausea; difficulty chewing; difficulty swallowing; anxiety; constipation 
and vomiting. For each symptom the question was asked: ‘How often have you experienced 
this symptom during the past three days?’, scored on a 5 point Likert scale, ranging from 1=“not 
at all” to 5=“a lot”. If participants did not answer the symptoms questionnaires within 3 days 
after complete the 24h dietary recall, we did not include their data in the analyses. In total, we 
collected n=274 recalls from patients and n=205 recalls from women without breast cancer. A 
number of n=205 recalls from breast cancer patients and n=152 recalls from women without 
cancer were used in the analyses in this paper. Excluding participants who did not complete the 
questionnaires within 3 days from analysis did not significantly influence the results on energy 
and macronutrient intake.
Demographics and medical information
All participants filled out a baseline questionnaire for demographic information, including age, 
smoking status and educational level. Information on stage of cancer at diagnosis and treatment 
were obtained from reviewing patients’ medical records. Dates of chemotherapy cycles were 
compared with the dates of the 24h-recalls to classify the recalls into the week within a 
chemotherapy cycle and to the number of cycles that was administered at the date of the 24h 
recalls. 
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Data analysis
Population characteristics were described as medians with interquartile range (IQR) or 
percentages of the patient and comparison group separately. To assess differences in the 
population characteristics between the groups, the Mann-Witney U-test was used for continuous 
data and the Chi Square test for categorical data. Differences in dietary intake at study onset 
(FFQ) between the women with and without breast cancer were analysed with Linear Regression. 
Mixed Model analysis was used to assess differences in energy, macronutrient and food group 
intake between the patient and comparison group. For the analysis of differences in dietary intake 
within a chemotherapy cycle for patients receiving a three weekly scheme of chemotherapy, 
recalls were classified according to the week within a chemotherapy cycle a 24h-recall was 
administered (week 1, week 2 or week 3) and to the number of cycles administered. Patients with 
weekly chemotherapy cycles were excluded from this analysis (n=22 recalls). Mixed models were 
also used to assess the association between symptoms and energy intake. Interactions between 
each symptom and group (patient and comparison group) were evaluated to test whether 
associations between symptoms and energy intake were different between the two groups. 
For significant interactions (p-value ≤0.1), stratified results for patients and the comparison 
group are shown. For symptoms with a significant association with energy intake, data was 
also analysed for the macronutrients protein, carbohydrates and fat. Covariates considered as 
potential confounders were included in the regression and mixed models analyses based on 
literature and change of regression coefficient. Variables that changed the regression coefficient 
≥ 10% in the adjusted model compared to the crude model were included in the final model. 
Final regression and mixed models analyses were adjusted for: age at inclusion, BMI at inclusion, 
education level, and smoking status at inclusion. Statistical analyses were performed using SPSS, 
version 21 (SPSS inc. Chicago, IL). A p-value < 0.05 was considered as statistically significant.
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Results
Patient characteristics
Data were collected for 117 breast cancer patients and 88 women in the comparison group, 
see table 5.1. BMI was higher in women with breast cancer than in women without breast 
cancer. In the patient group, fewer women had a high educational level than in the comparison 
group. There were no differences for age, smoking status and menopausal status between the 
groups. The majority of the breast cancer patients had a stage 2 tumour, and received adjuvant 
chemotherapy combining taxanes and anthracyclines. 
Table 5.1. Demographic and clinical characteristics of the patient and comparison group included in the study.
    Abbreviations: IQR, Interquartile range;  
    Missings per variable : education, 2; smoking, 1.
 * p <0.05
Dietary intake at study onset
At study onset, mean energy, protein, fat and carbohydrate intakes were similar between the 
patient and comparison group as assessed with a food frequency questionnaire (table 5.2). 
Table 5.1. Demographic and clinical characteristics of the patient and comparison group included in the study. 
Characteristic Comparison group 
(n=88) 
Patient group 
(n=117) 
Demographics    
Age, years (median, IQR)  53.5 (46.1 – 60.9) 51.0 (46.8 – 55.3) 
Education level  (n, %) * 
  Low 
  Medium 
  High  
4 (4.5) 
18 (20.5) 
66 (75.0) 
12 (10.4) 
35 (30.4) 
68 (59.1) 
Lifestyle   
BMI, kg/m2 (median, IQR) * 23.8 (22.1 – 26.7) 25.2 (22.3 – 28.4) 
Smoking status (n, %) 
   Current 
   Former 
   Never 
9 (10.2) 
40 (45.5) 
39 (44.3) 
21 (18.1) 
49 (42.2) 
46 (39.7) 
Medical profile   
Tumor Stage (n, %) 
  I 
 II 
 III 
 
25 (21.4) 
70 (59.8) 
22 (18.8) 
Adjuvant chemotherapy (n, %) 
Neo adjuvant chemotherapy (n, %) 
68 (58.1) 
49 (41.9) 
Chemotherapy regimen (n, %) 
  Taxanes only 
  Anthracyclines only 
 Taxanes + Anthracyclines  
 
4 (3.4) 
4 (3.4) 
109 (93.2) 
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Women with breast cancer reported to consume less alcohol than women in the comparison 
group. Intake for the various food groups was similar between the two groups, with the exception 
of cheese intake, which was slightly higher in breast cancer patients compared to the women 
without cancer.
Dietary intake during chemotherapy
In total, 357 recalls were collected, 205 in the patient group and 152 in the comparison group. 
During chemotherapy, breast cancer patients had a significantly lower energy intake than the 
women without cancer as assessed with 24h dietary recalls, 1779 ± 56 vs 1993 ± 68 kcal (table 
5.3). Breast cancer patients reported a significant lower absolute intake of protein, fat, and 
alcohol, but not of carbohydrates and fibre than women without cancer.  Expressed as energy 
percentages, during chemotherapy women with breast cancer consumed relatively more energy 
from carbohydrates and less energy from alcohol compared to women without cancer.
During chemotherapy, women with breast cancer consumed less energy from the food groups 
legumes; pastry and biscuits; cheese; and meat than the women without cancer (table 5.4). The 
intake of other food groups: bread; cereal and cereal products; fruit; vegetables; nuts, seeds and 
snacks; soups; soy and vegetarian products; sugar, sweets, sweet toppings and sweet sauces; 
milk and dairy products; cheese; eggs; and fish was similar between breast cancer patients 
during chemotherapy and women without cancer. Results expressed in grams/day can be found 
in Supplementary table 5.1. The main sources of total protein, fat and carbohydrate intake were 
similar for the patient and the comparison group. The main sources of protein intake were meat, 
bread and milk and dairy products. For fat the main sources were fats, oils and savoury sauces, 
cheese and meat, Carbohydrates came mostly from the food groups bread, alcoholic and non-
alcoholic drinks, milk and dairy products and fruit.
Dietary intake in the patient group was lower compared to the women without cancer in all three 
weeks after chemotherapy was administered, and was lowest in each first week However, there 
were no statistically significant  differences in energy and macronutrient intake between the first, 
second and third week within a chemotherapy (Supplementary table 5.2). In addition, there was 
no association between dietary intake and the number of chemotherapy cycles administered.
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Table 5.2. Habitual intake of energy, macronutrients and food groups for the patient and comparison 
group (mean ± SE) and differences in intake between the groups at study onset, assessed by a food 
frequency questionnaire.
a Adjusted for age, BMI, education level, smoking status
 * p <0.05
Table 5.2. H bitual intake of energy, macronutr ents and food groups for the patient and comparison group (mean ± SE) and 
differ ces in intake betwe n the groups at study onset, assessed by a food frequency questionnaire. 
 
 
 Intake in kcal (mean ± SE)  
 
Comparison group 
(N=88) 
Patient group 
(N=114) 
Differencea 
[95% CI] 
Energy 2069 ± 69.2 2070 ± 59.7 
1 
[-181 ; 184] 
Protein 318 ± 10.1 315 ± 8.7 
-3 
[-30 ; 24] 
Carbohydrate 859 ± 31.3 870 ± 27.0 
11 
[-71 ; 93] 
Fat 761 ± 32.3 779 ± 27.8 
18 
[-67 ; 103] 
Alcohol* 75 ± 7.5 51 ± 6.5 
-24 
[-44 ; -4] 
Fibre 46 ± 1.6 45 ± 1.4 
-1 
[-5 ; 3] 
Food groups    
Bread 256 ± 16.7 256 ± 14.4 
0 
[-44 ; 44] 
Cereal and cereal 
products 
139 ± 10.9 131 ± 9.4 
-8 
[-37 ; 21] 
Fruit 134 ± 8.3 118 ± 7.2 
-16 
[-37 ; 7] 
Vegetables 50 ± 3.5 53 ± 3.0 
3 
[-6 ; 12] 
Legumes 10 ± 1.6 11 ± 1.4 
1 
[-4 ; 5] 
Nuts, seeds and snacks 168 ± 15.7 146 ± 13.5 
-22 
[-63 ; 19] 
Soups 24 ± 3.3 22 ± 2.8 
-2 
[-11 ; 6] 
Soy products and 
vegetarian products 
18 ± 5.3 16 ± 4.5 
-2 
[-15 ; 12] 
Pastry and biscuits 119 ± 11.3 136 ± 9.7 
17 
[-13 ; 47] 
Sugar, candy, sweet 
toppings and sweet 
sauces 
110 ± 10.6 120 ± 9.2 
10 
[-18 ; 38] 
Milk and dairy products 195 ± 13.9 173 ± 12.0 
-22 
[-58 ; 15] 
Cheese* 105 ± 13.8 145 ± 11.9 
40 
[3 ; 76] 
Eggs 25 ± 2.6 24 ±2.3 
-1 
[-8 ; 6] 
Meat, meat products 
and poultry 
153 ± 9.3 159 ± 8.0 
6 
[-19 ; 30] 
Fish 36 ± 3.1 29 ± 2.7 
-7 
[-15 ; 1] 
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Table 5.3. Energy and macronutrient intake in kcal and energy percentages (en%) for the breast 
cancer patients during chemotherapy and comparison group during follow up (mean ± SE) and the 
differences in intake between the groups. 
 
 
Energy* 1993 ± 68.3 1779 ± 55.7 
-214 
[-353 ; -76] 
Protein* 313 ± 10.7 270 ± 8.8 
-43 
[-64 ; -21] 
Carbohydrate 844± 34.4 815± 28.0 
-29 
[-99 ; 41] 
Fat* 734 ± 32.0 633± 26.1 
-101 
[-166 ; -37] 
Alcohol* 54 ± 9.4 17 ± 7.7 
-37 
[-57 ; -19] 
Dietary fibre 38 ± 1.8 35 ± 1.4 
-3 
[-7 ; 1] 
  
Protein 16.3 ± 0.45 15.5 ± 0.37 
-0.8 
[-1.6 ; 0.2] 
Carbohydrate* 41.9 ± 1.0 46.2 ± 0.82 
4.3 
[2.2 ; 6.3] 
Fat 36.6 ± 0.85 35.0 ± 0.70 
-1.6 
[-3.4 : 0.1] 
Alcohol* 2.8 ± 0.47 0.8 ± 0.38 
-2.0 
[-2.9 ; -1.0] 
Dietary fibre 2.0 ± 0.09 2.0 ± 0.07 
0.0 
[-0.1 ; 0.2] 
Table 5.3. Energy and macronutrient intake in kcal and energy percentages (en%) for the breast cancer 
patients during chemotherapy and comparison group during follow up (mean ± SE) and the differences in 
intake between the groups.
                                                              Intake in kcal (mean ± SE)
 Comparison group Patient group Differencea
   [95% CI]
                                                              Intake in en% (mean ± SE)
a Adjusted for age, BMI, education level, smoking status
 * p <0.05
Table 5.3. Energy and macronutrient intake in kcal and energy percentages (en%) for the breast 
cancer patients during chemotherapy a d comparison group during follow up (mean ± SE) a d the 
differ nc s in intake between the groups. 
 
 
Energy* 1993 ± 68.3 1779 ± 55.7 
-214 
[-353 ; -76] 
tein* 13 ± 10.7 270 ± 8.8 
-43 
[-64 ; -21] 
r ohydrate 844± 34.4 815± 28.0 
-29 
[-99 ; 41] 
Fat* 734 ± 32.0 633± 26.1 
-101 
[-166 ; -37] 
Alcohol* 54 ± 9.4 17 ± 7.7 
-37 
[-57 ; -19] 
Dietary fibre 38 ± 1.8 35 ± 1.4 
-3 
[-7 ; 1] 
  
Protein 16.3 ± 0.45 15.5 ± 0.37 
-0.8 
[-1.6 ; 0.2] 
Carbohydrate* 41.9 ± 1.0 46.2 ± 0.82 
4.3 
[2.2 ; 6.3] 
Fat 36.6 ± 0.85 35.0 ± 0.70 
-1.6 
[-3.4 : 0.1] 
Alcohol* 2.8 ± 0.47 0.8 ± 0.38 
-2.0 
[-2.9 ; -1.0] 
Dietary fibre 2.0 ± 0.09 2.0 ± 0.07 
0.0 
[-0.1 ; 0.2] 
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Table 5.4. Intake per food group for the breast cancer patients during chemotherapy and comparison 
group during follow up (mean ± SE) and the differences in intake between the groups in kcal. 
a Adjusted for age, BMI, education level, smoking status
 * p <0.05
Table 5.4. Intake per food group for the breast cancer patients during chemotherapy and comparison group 
during follow up (mean ± SE) and the differences in intake between the groups in kcal. 
 Intake in kcal* (mean ± SE)  
Comparison group Patient group 
Difference 
[95% CI]a 
Bread 332 ± 39.5 291 ± 37.2 
-41 
[-81 ; 2] 
Cereal and cereal products 68 ± 29.4 67 ± 27.7 
-1 
[-32 ; 31] 
Fruit 98 ± 26.5 86 ± 24.9 
-121 
[-40 ; 16] 
Vegetables 41 ± 9.4 33 ± 8.9 
-8 
[-17 ; 3] 
Legumes* 136 ± 39.2 83  ± 36.9 
-53 
[-95 ; -12] 
Nuts seeds and snacks 7 ± 11.8 9 ± 11.1 
2 
[-11 ; 14] 
Soups 35 ± 28.5 22 ± 26.8 
-13 
[-43 ; 18] 
Soy products and vegetarian 
products 
29 ± 14.9 31 ± 14.0 
2 
[-14 ; 18] 
Pastry and biscuits* 131 ± 36.6 84 ± 34.4 
-47 
[-86 ; -8] 
Sugar, candy, sweet toppings, 
and sweet sauces 
90 ± 28.7 86 ± 27.0 
-4 
[-34 ; 26] 
Milk and dairy products 164 ± 36.6 170 ± 34.5 
6 
[-33 ; 44] 
Cheese* 140 ± 22.4 112 ± 21.1 
-28 
[-52 ; -4] 
Eggs 35 ± 9.1 39 ± 8.6 
4 
[-6 ; 14] 
Meat, meat products and 
poultry* 
190 ± 31.8 150 ± 29.9 
-40 
[-74 ; -6] 
Fish 25 ± 22.3 42 ± 20.95 
17 
[-8 ; 40] 
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Symptoms
During chemotherapy, the patient group scored significantly lower on their self-reported taste, 
smell, appetite and hunger, compared to the women without cancer (table 5.5). Furthermore, 
breast cancer patients undergoing chemotherapy experienced more often anxiety, dry mouth, 
constipation, feeling depressed, thick saliva, diarrhoea, sore mouth, lack of energy, nausea, 
difficulty chewing and difficulty swallowing than women in the comparison group (table 5.6). 
Scores were not different for the symptoms pain and vomiting between the patient and the 
comparison group. Only 3 women with breast cancer and 1 woman without breast cancer 
reported vomiting as a symptom they experienced that day, therefore vomiting was not analysed 
for its association with energy intake.
Table 5.5. Taste, smell, appetite and hunger scores from AHSP questionnaire for the breast cancer 
patients during chemotherapy and comparison group during follow up (mean ± SE) and the association 
of AHSP categories with energy intake (kcal). Higher scores indicate a more positive self-judgement on 
the categories of the questionnaire. β for energy intake is the difference in energy intake (kcal) per 1 unit 
higher score within ASHP category.
a Adjusted for age, BMI, education level, smoking status
 * p <0.05
  Score questionnaire (mean ± SE)  
Category Range Comparison 
group 
Patient group Difference Estimate (β) for energy intake 
(kcal)a [95% CI] 
Taste 8-40 30.9 ± 0.71 22.0 ± 0.57 
-8.9* 
[-10.4 ; -7.5] 
16.4* 
[7.0 ; 25.8] 
Smell 6-30 23.3 ± 0.42 20.6 ± 0.42 
-2.7* 
[-3.7 ; -1.8] 
11.9 
[-5.0 ; 28.7] 
Appetite 6-30 24.7 ± 0.40 18.7 ± 0.50 
-6.0* 
[-7.0 ; -5.0] 
26.5* 
[14.4 ; 38.5] 
Hunger 9-45 38.3 ± 0.70 32.5 ± 0.70 
-5.8* 
[-7.4 ; -4.3] 
24.5* 
[15.1 ; 33.9] 
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Symptoms and dietary intake
A higher self-judgement of taste perception, better appetite and more hunger were significantly 
associated with a higher energy intake (table 5.5). Self-judgement of smell was not significantly 
associated with energy intake. 
Having a dry mouth, lack of energy, nausea and having difficulty chewing were significantly 
associated with a lower energy intake (table 5.6). The associations between anxiety and energy 
intake and between constipation and energy intake were different for the patient and the 
comparison group (interaction anxiety p=0.02, constipation p=0.03): anxiety was not associated 
with energy intake in breast cancer patients, while it was associated with a lower energy intake 
in the comparison group. Constipation was associated with a higher energy intake in the patient 
group and with a lower energy intake in the comparison group, but these associations were not 
statistically significant (table 5.6). 
For the symptoms that were significantly associated with energy intake, we additionally assessed 
whether those symptoms  were associated with protein, carbohydrate and fat intake. Briefly, 
those associations were in the same direction as how the intake of macronutrients differed 
during chemotherapy between the patients and the comparison group: symptoms were 
associated with a lower protein and fat intake, and not associated with the intake of carbohydrates 
(Supplementary table 5.3).
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Table 5.6. Results of the symptom questionnaire for the breast cancer patients during chemotherapy and 
comparison group during follow up (mean ± SE) and the association between symptoms and energy intake 
(kcal). Symptom severity was assessed on a 5 point Likert scale (1=not at all, 5=a lot). β for energy intake 
indicates the difference in energy intake (kcal) per 1 unit higher score in the symptom.
a  Adjusted for age, BMI, education level, smoking status
b  For anxiety and constipation significant interactions were found on the association with energy intake, therefore stratified 
results are shown.
c  For vomiting only 1 control and 3 patients reported a score of 2 or higher on the questionnaire, therefore this symptom 
was not analysed for the association with energy intake.
Score questionnaire (mean ± SE) 
Symptom Comparison group Patient group Difference Estimate (β) for energy intake 
(kcal)a [95%CI] 
Pain 1.6 ± 0.13 1.9 ± 0.11 
0.3 
[-0.005 ; 0.520] 
54.2 
[-2.8 ; 111.2] 
Dry mouth 1.3 ± 0.15 2.9 ± 0.12 1.6 [1.3 ; 1.9]* 
-47.1* 
[-92.5 ; -1.8] 
Depressed 1.3 ± 0.1 1.6 ± 0.08 0.3 [0.1 ; 0.5]* 
5.4 
[-68.4 ; 79.1] 
Thick saliva 1.1 ± 0.12 1.9 ± 0.10 0.8 [0.6 ; 1.1]* 
-56.3 
[-114.1 ; 1.5] 
Diarrhoea 1.0 ± 0.09 1.5 ± 0.07 0.5 [0.2 ; 0.6]* 
-3.1 
[-75.9 ; 69.6] 
Sore mouth 1.3 ± 0.13 2.2 ± 0.11 0.9 [0.7 ; 1.2]* 
-35.7 
[-86.0 ; 14.6] 
Lack of energy 1.6 ± 0.14 3.3 ± 0.12 1.7 [1.5 ; 2.0]* 
-55.5* 
[-99.0 ; -12.1] 
Nausea 1.1 ± 0.1 1.7 ± 0.08 0.6 [0.4 ; 0.8]* 
-77.7* 
[-139.4 ; -16.0] 
Difficulty chewing 1.1 ± 0.09 1.5 ± 0.07 0.4 [0.2 ; 0.6]* 
-102.6* 
[-180.3 ; -24.9] 
Difficulty 
swallowing 
1.1 ± 0.08 1.5 ± 0.06 0.4 [ 0.2 ; 0.6]* 
-33.6 
[-117.1 ; 49.8] 
Constipationb 1.3 ± 0.12 1.8 ± 0.09 0.5 [0.2 ; 0.7]*  
Constipation 
control 
   
-103.3 
[-228.8 ; 22.3] 
Constipation 
patient 
   
42.1 
[-34.1 ; 118.5] 
Anxietyb 1.2 ± 0.08 1.5 ± 0.07 0.3 [0.1 ; 0.4]*  
Anxiety Control    
-208.7* 
[-384.1 ; -33.3] 
Anxiety Patient    
83.1 
[-18.2 ; 184.5] 
Vomitingc 1.0 ± 0.04 1.1 ± 0.03 0.04 [-0.04 ; 0.12]  
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Discussion
To date, this is the largest study that examined energy, macronutrient and food group intake 
in breast cancer patients during chemotherapy compared to a group of women without 
cancer. We showed that breast cancer patients had a significantly lower energy intake during 
chemotherapy compared with a group of women without cancer. Since habitual intake of breast 
cancer patients before start of chemotherapy was comparable to the women without cancer in 
our study, we can assume that the differences found between the groups were mostly due to the 
consequences of chemotherapy. These findings are  in accordance with two other studies that 
observed a lower energy intake in breast cancer patients during chemotherapy compared to 
before chemotherapy7,8. Only one previous study, published in 1987, suggested a higher dietary 
intake during chemotherapy in breast cancer patients compared with controls6. However, that 
study had a control group which already had a lower intake at baseline, limiting the reliability of 
those conclusions. 
The lower energy intake that we observed during chemotherapy was not caused by a lower intake 
of all macronutrients. The intakes of fat, protein and alcohol were lower during chemotherapy 
in breast cancer patients than in women without cancer, while intakes of carbohydrates and 
dietary fibre were similar. The lower protein and fat intake can be explained by the food groups 
that were consumed less during chemotherapy: meat and cheese are mostly high in protein 
and fat, and may thereby partially account for the different intakes of macronutrients. Habitual 
alcohol intake was lower in breast cancer patients before chemotherapy than women without 
cancer, and the intake remained lower during chemotherapy. As alcohol is a known risk factor 
for breast cancer21, a higher or comparable alcohol intake could be expected in the patient 
group compared wo the women without cancer. Possibly, breast cancer patients underreported 
their alcohol intake due to social desirability bias. However, it is also possible that breast cancer 
patients changed their dietary habits due do cancer diagnosis. Cancer diagnosis has been 
referred to as a ‘teachable moment’ for lifestyle changes and may motivate patients to change 
their dietary habits22. 
Patients in our study experienced a variety of symptoms during chemotherapy, but not all were 
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associated with energy intake. Specifically, the symptoms of lower self-reported taste, lower 
appetite, less hunger, dry mouth, lack of energy, nausea and difficulty chewing were associated 
with a lower energy intake. These symptoms are known to limit the enjoyment of eating as they 
make eating more difficult. It is thus not surprising that they have been previously related to a 
lower energy intake4,23. Interestingly, self-judgement of taste was significantly associated with 
energy intake, but self-judgement of smell was not, while smell function is generally recognized 
as an important factor for food intake24. We must consider that humans are generally not well 
able to rate their own smell sensitivity25. Therefore, we cannot exclude that reduced smell 
function influences energy intake. The experience of symptoms does not only have an effect 
on dietary intake, symptoms also negatively impact quality of life26. Therefore it is important to 
monitor symptoms during chemotherapy, and to treat symptoms where possible. Furthermore, 
given the associations of symptoms with dietary intake, it is important to monitor nutritional 
status to ensure an adequate intake of energy and nutrients during chemotherapy. 
In addition to experienced symptoms, changed preferences for foods may be related to the 
changed food choices we observed during chemotherapy. Aversions for meat are commonly 
reported during chemotherapy27,28, and may thereby underlie the lower intake of this food group 
that we observed in breast cancer patients during chemotherapy compared to the women without 
cancer. However, research on food preferences during chemotherapy is mostly anecdotal and 
scarcely measured quantitatively and should be taken into account in future studies. 
Studies suggest that breast cancer patients gain weight during and after chemotherapy13,14. 
To date, it is not clear which factors underlie these weight changes. However, our study does not 
suggest nutritional intake as a contributing factor for this weight gain, as we observe a decreased 
energy intake of patients during chemotherapy. However, breast cancer patients may have a 
lower energy requirement, as physical activity may be lower9,29. Additionally, reductions in resting 
energy expenditure have been reported during and after chemotherapy13,14. Therefore, studies 
assessing weight change during chemotherapy should take changes in dietary intake, physical 
activity and resting energy expenditure into account to assess the contribution of these factors 
on weight change.
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Previous studies investigating dietary intake during chemotherapy in breast cancer patients 
were heterogeneous in the time points dietary intake was assessed. Mostly, it was assessed the 
week before a next cycle would be administered. In our study, we deliberately chose to assess 
dietary intake at random days during the full cycle of chemotherapy, thereby capturing the full 
variation in dietary intake over chemotherapy. Although there were no significant differences 
between the weeks within chemotherapy cycles, there was variation within the weeks; dietary 
intake was lowest in the first week after a cycle was administered. This renders the importance 
to take into account all weeks within chemotherapy cycles to give a correct representation of 
dietary intake during chemotherapy. 
It cannot be excluded that differential reporting of dietary intake between patients and the 
comparison group influenced the results of our study. Differential reporting may be influenced 
by differences in BMI30. BMI was slightly higher in the patient group than the comparison group 
at the start of our study. As persons with higher BMI tend to underestimate dietary intake, 
the patient group may have underestimated their intake, explaining the difference in intake 
between women with breast cancer and women without cancer observed during chemotherapy. 
However, habitual intake was similar between patients and the comparison group at baseline 
and analyses were adjusted for BMI. Therefore, we do not expect that differential reporting 
substantially influenced our results.
In conclusion, our study is the largest study to date showing that breast cancer patients have 
a lower dietary intake during chemotherapy, which is expressed in a lower intake of specific 
food groups. The lower intake was associated with specific symptoms. These finding can guide 
clinicians to inform patients about the potential impact of chemotherapy and related symptoms 
on dietary intake and to ensure an adequate intake of energy and nutrients during chemotherapy. 
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Supplementary table 5.1. Intake per food group for the breast cancer patients during chemotherapy and 
comparison group during follow up (mean ± SE) and the differences in intake  between the groups in 
grams.
a Adjusted for age, BMI, education level, smoking status
 * p <0.05
 Intake in gram 
(mean ± SE) 
 
Comparison group Patient group Difference 
[95% CI]a 
Bread 124 ± 15.3 110 ± 14.4 
-14 
[-31 ; 2] 
Cereal and thickeners 35 ± 17.4 37 ± 16.4 
2 
[-16 ; 21] 
Fruit 131 ± 34.8 125 ± 32.8 
-6 
[-43  ; 31] 
Vegetables 152 ± 29.1 125 ± 27.4 
-27 
[-58 ; 4] 
Legumes* 33  ± 10.4 19  ± 9.8 
-14 
[-25 ; -3] 
Nuts seeds and snacks 14 ± 18.1 8 ± 17.1 
-6 
[-25 ; 13] 
Soups 25 ± 19.5 21 ± 18.4 
-4 
[-25 ; 17] 
Soy products and 
vegetarian products 
76 ± 29.9 77 ± 28.1 
1 
[-31 ; 33] 
Pastry and biscuits* 40 ± 11.2 25 ± 10.5 
-15 
[-27 ; -3] 
Sugar, candy, sweet 
toppings, and sweet 
sauces 
22 ± 6.4 21 ± 6.0 
-1 
[-7 ± 6] 
Milk and dairy products 260 ± 54.8 247 ± 51.7 
-13 
[-70 ; 44] 
Cheese* 39 ± 6.5 31 ± 6.1 
-8 
[-15 ; -1] 
Eggs 27 ± 6.6 30 ± 6.2 
3 
[-5 ; 9] 
Meat, meat products and 
poultry* 
92 ± 14.4 76 ± 13.6 
-16 
[-32 ; -1] 
Fish 18 ± 12.4 20 ± 11.7 
2 
[-11 ± 16] 
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Supplementary table 5.2. Energy and macronutrient intake per week within the chemotherapy cycle. Week 
1: n=90 recalls, week 2: n= 60 recalls, week 3: n=42 recalls.
a Adjusted for age, BMI, education level, smoking status
Supplementary table 5.3. The association of AHSP and symptom categories and intake of protein, 
carbohydrate and fat (kcal) for the categories that were significantly associated with energy intake.Supplemen ary table 5.3. The association f AHSP and symptom tegorie  and intake of protein, c rbohydrate 
and fat (kcal) for the categories that were significantly associated with energy intake.  
Symptom 
Estimate (β) for protein 
intake (kcal)1 
[95%CI] 
Estimate (β) for 
carbohydrate intake 
(kcal)a 
[95%CI] 
Estimate (β) for fat intake 
(kcal)a 
[95%CI] 
Tasteb 
3.5* 
[2.0 ; 5.0] 
2.6 
[-2.1 ; 7.3] 
7.7* 
[3.3 ; 12.1] 
Appetiteb 
5.1* 
[3.1 ; 7.1] 
5.5* 
[0.6 ; 11.5] 
12.6* 
[6.9 ; 18.3] 
Hungerb 
4.2* 
[2.7 ; 5.7] 
8.5* 
[3.8 ; 13.2] 
10.2* 
[5.7 ; 14.7] 
Dry mouthc 
-8.0* 
[-15.7; -0.4] 
-7.9 
[-30.3; 14.5] 
-21.0 
[-42.6; 0.7] 
Lack of energyc 
-12.2* 
[-19.5 ; -4.8] 
-12.0 
[-33.5 ; 9.5] 
-22.6* 
[-43.4 ; -1.8] 
Nauseac 
-11.1* 
[-21.9 ; -0.2] 
-8.6 
[-39.1 ; 21.9] 
-42.4* 
[-72.3 ; -12.5] 
Difficulty chewingc 
-14.9* 
[-28.4 ; -1.3] 
-20.2 
[-58.6 ; 18.2] 
-61.6* 
[-99.0 ; -24.2] 
a Adjusted for age, BMI, education level, smoking status 
b β for macronutrient intake is the difference in macronutrient intake (kcal) per 1 unit higher score within ASHP category. 
c β for macronutrient intake indicates the difference in macronutrient intake (kcal) per 1 unit higher score in the symptom. 
*p < 0.05 
 
Supplementary table 5.2. Energy and macronutrient intake per week within the chemotherapy cycle. Week 1: n=90 
recalls, w ek 2: n= 60 recalls, w ek 3: n=42 recalls. 
 Intake in kcal* 
(mean ± SE) 
Difference 
[95% CI]a 
Energy 
          Week 1 
          Week 2 
          Week 3 
 
1751 ± 74.1 
1883 ± 84.0 
1861 ± 95.6 
 
Ref 
132 [-54 ; 318] 
110 [-96 ; 315] 
Protein 
          Week 1 
          Week 2 
          Week 3 
 
267 ± 12.6 
286 ± 14.4 
283 ± 16.5 
 
Ref 
19 [-14 ; 52] 
16 [-21 ; 53] 
Fat 
         Week 1 
         Week 2 
         Week 3 
 
621 ± 34.2 
665 ± 39.0 
671 ± 44.3 
 
Ref 
43 [-44 ; 130] 
50 [-47 ; 146] 
Carbohydrate 
         Week 1 
         Week 2 
         Week 3 
 
816 ± 38.1 
863 ± 42.9 
847 ± 48.1 
 
Ref 
47 [-45 ; 139] 
30 [-71 ; 131] 
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This thesis aims to assess among stage I-IIIB breast cancer patients:
1. the association between pre-treatment body composition and dose-limiting toxicities du-
ring chemotherapy.
2. potential changes in body weight and body composition during and after chemotherapy 
compared to changes in age-matched women without cancer in the same time period.
3. dietary intake during chemotherapy compared to age-matched women without cancer in 
the same time period.
After summarizing the main findings of this thesis, methodological considerations including 
comparison with other studies and changes in breast cancer care will be discussed. This will be 
followed by the final conclusion and implications for clinical practice and future research.
Main findings
Pre-treatment body composition and dose-limiting toxicities during chemotherapy
The first aim of this thesis was to assess the association between pre-treatment body weight 
and body composition and dose-limiting toxicities during chemotherapy. We assessed body 
weight and body composition before chemotherapy in the COBRA-study by Dual Energy X-ray 
Absorptiometry (DEXA)-scan and obtained information regarding toxicities during chemotherapy 
from medical records (chapter 2). Results of our study showed that a higher BMI and a higher 
fat mass (kg and percentage) are associated with an increased risk of dose-limiting toxicity, while 
lean body mass (kg) is not associated with risk of toxicities. This suggests that total fat mass 
determines the risk of dose-limiting toxicities during chemotherapy in breast cancer patients.
Changes in body weight and body composition during chemotherapy
The second aim of this thesis was to assess changes in body weight and body composition 
during chemotherapy. We assessed this using two methods; a meta-analysis and analyses within 
the COBRA-study (chapter 3 and 4).
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Our meta-analysis (chapter 3), included 25 papers, showed an overall body weight gain of 2.7 
kg (95% CI: 2.0-3.3) during chemotherapy in breast cancer patients. Meta-regression showed 
that studies including women treated with cyclophosphamide, methotrexate and 5-fluorouracil 
(CMF) regimes reported a greater weight gain than studies including only women treated with 
newer, anthracycline and/or taxane based regimes. Body weight gain was also more pronounced 
in women who participated in studies that were published before 2000 than in those published 
after 2000.
The results of the COBRA-study (chapter 4), in which we prospectively followed changes in 
body weight and body composition during chemotherapy and 6 months after chemotherapy 
showed that women with breast cancer on average gained 1.1 kg body weight from baseline to 
shortly after chemotherapy. This was similar to the 1.4 kg body weight gain we found in a sub-
analysis of our meta-analysis of studies including only women treated with newer chemotherapy 
regimes. We also showed that 6 months after chemotherapy body weight in the patient group 
was not different from baseline body weight. Women in the comparison group had no significant 
changes in body weight and body composition during the study period.
We showed that patients increased their lean body mass (kg) from baseline to shortly after 
chemotherapy. However, 6 months after chemotherapy lean mass had returned to baseline 
values and there were no differences in fat mass (kg) between the patient group and the 
comparison group of women without cancer. This suggests that the increase in lean body mass 
was only temporary. 
From baseline to shortly after chemotherapy breast cancer patients had a stable fat mass. Six 
months after chemotherapy fat mass slightly, yet significantly, increased compared to baseline 
and compared to the period shortly after chemotherapy. Fat mass did not significantly differ 
over time between patients and women without cancer and there were no differences in fat 
mass between the two groups at all three time points. 
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Differences in dietary intake during chemotherapy 
A third aim of this thesis was to assess differences in dietary intake during chemotherapy 
between women with breast cancer and a comparison group of women without cancer. Again 
we assessed this within the COBRA-study, using a Food Frequency Questionnaire (FFQ) to assess 
usual dietary intake before chemotherapy and twice utilizing a 24-hr dietary recall to assess 
actual dietary intake at two random days during chemotherapy among patients and twice during 
the same time frame among women in the comparison group (chapter 5). 
Before the start of chemotherapy, women with breast cancer had a similar energy and 
macronutrient intake as women in the comparison group. During chemotherapy, women with 
breast cancer showed a lower intake of energy, total fat, total protein and alcohol than women 
without cancer, while there was no difference in total carbohydrate intake between the groups. 
The lower intake of energy, total fat and total protein was explained by a lower intake of pastry 
and biscuits, cheese, legumes, and meat products. 
We assessed within the COBRA-study whether dietary intake before chemotherapy, eating 
style (restrained, emotional, external), or appetite, taste, and smell during chemotherapy were 
associated with greater changes in body weight, fat mass, and lean body mass over time (chapter 
4). A higher score on appetite during chemotherapy was associated with greater changes in body 
weight, fat mass, or lean body mass over time. We showed that a younger age was associated 
with greater changes in body weight and fat mass over time, but not with changes in lean 
body mass over time. In addition, an ER-receptor negative tumour was associated with greater 
changes in body weight over time, but not with changes in fat mass or lean body mass over time 
(chapter 4). Baseline dietary intake, eating style, and taste and smell during chemotherapy were 
not associated with changes in body weight or body composition over time. 
Summarizing, pre-treatment body composition (e.g. fat mass) is associated with dose-limiting 
toxicities during chemotherapy. Body weight gain during chemotherapy appears to be mainly 
an increase in lean body mass and decreased in the 6 months after chemotherapy. Habitual 
dietary intake before start of chemotherapy is not associated with changes in body weight and 
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body composition over time. A higher appetite during chemotherapy is associated with greater 
changes in body weight and body composition over time. A younger age is associated with 
greater changes in body weight and fat mass over time, but not with changes in lean body mass 
over time. An ER-receptor negative tumour is associated with greater changes in body weight 
over time, but not with changes in body composition over time. During chemotherapy, breast 
cancer patients have a lower intake of energy, total fat, and total protein compared to age-
matched women without cancer in the same time period, which could be explained by a lower 
intake of pastry and biscuits, cheese, legumes, and meat products.
Methodological considerations including comparison with other studies
When interpreting these results and comparing the results with other studies, it is important 
to take into account methodological considerations. In this paragraph the internal and external 
validity of the COBRA-study will be discussed as compared to other studies. 
Internal validity
This section about the internal validity consists of four parts including: study design, 
information error and bias, confounding, and selection error and bias. Each part will be 
discussed separately. 
Study design
We conducted a prospective study among stage I-IIIB breast cancer patients treated with 
chemotherapy and compare their results with a comparison group of women without cancer 
of similar age during the same time period. Most published studies of changes in body weight 
and body composition during chemotherapy in breast cancer patients only included women 
treated with adjuvant chemotherapy1-29. Because the number of patients treated with neo-
adjuvant chemotherapy is increasing, we decided to include both patients receiving adjuvant 
and neo-adjuvant chemotherapy. As a consequence of this inclusion of adjuvant and neo-
adjuvant treated patients, participants were in different phases of breast cancer treatment at 
the moments of measurement within the COBRA-study, see figure 6.1.  
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Because neo-adjuvant chemotherapy starts shortly after diagnosis, the first moment of 
measurement had often be postponed from before the first cycle of chemotherapy to during 
the first cycle of chemotherapy. This could have influenced our baseline results on body weight, 
body composition, dietary intake, and physical activity, since minor changes in body composition 
could have occurred within the first cycle of chemotherapy and it could be more difficult to recall 
the situation before start of chemotherapy when patients are already receiving chemotherapy. 
For patients treated with adjuvant chemotherapy, body weight, body composition, physical 
activity and dietary intake may have been affected by the preceding surgery and/or radiotherapy. 
It is also possible that the different phases of treatment after chemotherapy had an influence on 
body weight and body composition. However, we do not expect that including patients treated 
with adjuvant and neo-adjuvant chemotherapy changed our conclusion, because associations 
between pre-chemotherapy body composition and dose-limiting toxicities were not different for 
patients receiving adjuvant chemotherapy versus patients receiving neo-adjuvant chemotherapy 
(chapter 2). In addition, changes in body weight and body composition or baseline dietary intake 
did not differ between patients receiving adjuvant chemotherapy and patients receiving neo-
adjuvant chemotherapy (chapter 4). In addition, changes in body weight and body composition 
did not differ between patients with a first measurement before chemotherapy versus patients 
with a first measurement during the first cycle of chemotherapy (chapter 4). Thus, including both 
adjuvant and neo-adjuvant treated patients did not affect the outcome of our study.
Figure 6.1. Schematic overview of moment of measurements for COBRA-study within treatment plan in 
patients treated with adjuvant chemotherapy (grey) and patients receiving neo-adjuvant chemotherapy 
(white).
One of the most important strengths of the COBRA-study compared to previous studies on 
changes in body weight and body composition is that we included a comparison group of 
women without cancer. This is important because all women change in body weight and body 
composition naturally over time, especially during menopause when they typically experience 
Diagnosis InclusionCOBRA-study
Baseline
measurement
Neo-adjuvant
chemotherapy
Measurements shortly
after chemotherapy
Measurements 6 months
after chemotherapy
Surgery (and
radiotherapy)
Endocrine
therapy
Diagnosis Surgery (andradiotherapy
Inclusion
COBRA-study
Baseline
measurement
Adjuvant
chemotherapy
Measurements shortly
after chemotherapy
Measurements 6 months
after chemotherapyEndocrine therapy
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an increase in body weight and fat mass and a decrease in lean muscle mass30. Because we 
included a comparison group, we were able to assess whether changes in body weight and 
body composition were different from natural changes over time (chapter 4). If we had chosen 
to only assess changes in fat mass in the patient group, we would have concluded that there is 
an increase in body fat over the study period. However, since we included a comparison group, 
we have been able to conclude that the increase in fat mass was not different from changes 
occurring naturally over time.
Information error and bias
Within the COBRA-study various instruments were used to collect data. Errors may be expected in 
our study measurements. When these errors were different between subgroups of our population 
with regard to the exposure and/or outcome this may have resulted in information bias. 
Within this paragraph, some considerations regarding the information error and bias of three 
important measurements within the COBRA-study will be discussed, including the measurements 
of body composition, missing information regarding medication use, and dietary intake. 
Body weight and composition
An important difference among studies is the method of data collection on body weight and 
body composition. Almost half of the included papers in our meta-analysis assessed body 
weight retrospectively by chart review2,3,6,10,18,19,22,24,25,31, while most studies which prospectively 
assessed body weight used a scale to assess body weight1,5,7,9,12-17,20.  Our meta-analysis showed 
that participants’ body weight gain was less in studies which prospectively assessed body weight 
compared to studies which retrospectively assessed body weight (chapter 2).
In contrast to our study, most previous studies which prospectively assessed body weight 
changes in breast cancer patients used a scale1,4,7,9,12-17,32. It was not feasible to measure body 
weight with a scale on each moment of measurement in our study. Therefore, we used body 
weight assessed using Dual-Energy X-ray Absorptiometry (DEXA)-scan in this study. In a subgroup 
of 60 participants including patients and women of the comparison group, we measured body 
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weight on a scale as well as with the DEXA-scan on all three time points. Data from this subgroup 
showed that absolute body weight assessed by DEXA-scan is slightly lower than body weight 
measured by a scale. However, in chapter 4 we showed that changes in body weight over time 
were similar and not significantly different as measured by DEXA scan or scale. This suggests 
that using a DEXA-scan to assess body weight did not influence our results.
Methods employed to assess body composition also varied among studies, including DEXA8,9,15-
17,23,32,33, bio electric impedance (BIA)4,11-13,15,26,27, and skinfold thickness5,7, which all have their 
advantages and disadvantages. DEXA is a very accurate and valid method to assess body 
composition34,35. It is shown that DEXA-scans are a sensitive tool to assess small changes in 
body composition over time36. At present, there are two main DEXA manufacturers, Lunar and 
Hologic, whose scanners are used in clinical practice. It is shown that different types of scanners 
produce different results on body composition37,38. In the COBRA-study, types of scanners 
differed between the hospitals, therefore participants were measured three times in the same 
hospital with the same scanner. 
A disadvantage of the use of DEXA-scan for measuring body composition during chemotherapy 
is the influence of body hydration on lean body mass results of the DEXA-scan39,40, as hydration 
status of the body may change during chemotherapy. However, an assumption of using BIA to 
estimate body composition is a fixed hydration status of the body; therefore in earlier studies 
using BIA4,11-13,15,26,27, changes in hydration status may also have caused inaccurate measures of 
body composition by BIA41.
Because hydration status can affect lean body mass results of the DEXA scan, the increase 
in lean body mass in the patient group that was observed during chemotherapy in our study 
could be due to an increase in body fluid, especially since it returned back to baseline values 
6 months after chemotherapy. One possible explanation for the increase in body fluid during 
chemotherapy could be the use of a more recent chemotherapy regime for breast cancer 
including docetaxel, which can cause fluid retention42. Besides docetaxel, dexamethasone, 
which is frequently prescribed during chemotherapy, can cause fluid retention as a side effect.
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Missing information regarding medication use
Information regarding use of medication is difficult to collect. Most studies did not include 
medication use or they collected data via medical records. In our study, information regarding 
use of medication was gathered via calendar log sheets. Each participant was asked to complete 
a calendar log sheet, on which information regarding type of drug, dose and amount was 
collected for the total study period. These data are important because anti-emetic drugs used 
in breast cancer treatment can influence body composition. Dexamethasone, for example, 
may cause fluid retention. Unfortunately, because many different drugs were used, it proved 
to be very difficult to get a complete overview of used medication used during chemotherapy, 
even with the log sheets. As a consequence, it was not possible to take medication use during 
chemotherapy into account in our analyses and to assess whether changes in lean body mass 
differed by medication use which is similar in other studies.
Dietary intake
In general, self-reported dietary assessment methods may be influenced by several errors 
including socially desirable answers, and the difficulty to recall past dietary intake and to correctly 
estimate portion sizes. 
Both the methods used and the time points when dietary intake was assessed are heterogeneous 
in previous studies. Methods commonly used to assess dietary intake in breast cancer patients 
are food records 8,11,12,14,32,33, food frequency questionnaires5,9 and 24-hr dietary recalls1,9. Most 
previous studies assessed dietary intake during chemotherapy in the week before the next 
chemotherapy infusion, while we assessed actual dietary intake on random days during the 
full cycle of chemotherapy using a 24-hr dietary recall. Since we assessed actual dietary intake 
during the full cycle of chemotherapy, we captured the full variation in dietary intake over the 
course of chemotherapy. Energy intake varied among the weeks of chemotherapy cycle in our 
study (chapter 5); with the lowest intake in the first week and the highest intake in the week prior 
to the next cycle, although this did not reach statistical significance.
We estimated habitual dietary intake with a FFQ. We used 24-hr dietary recalls to assess actual 
dietary intake because we expected a large day-to-day variation during chemotherapy in the 
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patient group. Because we included only two 24-hr dietary recalls per participant we could 
not precisely assess dietary intake on an individual level, however two 24-hr dietary recalls per 
participant can provide an accurate estimate of the mean for a group, although the standard 
deviation will be overestimated43. 
As a consequence of using a combination of FFQ and 24-hr dietary recall to assess dietary intake 
within the COBRA-study, it was not possible to assess changes in dietary intake of patients 
between the start and end of chemotherapy. However, it was possible to assess differences in 
dietary intake between the patient and comparison group (chapter 5) and to assess whether 
usual dietary intake before start of chemotherapy was associated with changes in body 
composition over time (chapter 4).
Differences in BMI between the patient and comparison group could induce differential 
misreporting, since persons with a higher BMI tend to underestimate dietary intake more than 
persons with a lower BMI. In the sample of participants included in chapter 5, BMI was 1.4 kg/
m2 higher than in the patient group. This could have resulted in more underreporting of dietary 
intake in the patient group, therefore differences between the patient and comparison group 
could be overestimated. 
Confounding 
Confounding variables are variables that are associated with outcome and exposure, but are 
not an intermediate. Most previous studies on changes in body weight or body composition 
in breast cancer patients did not adjust for any confounding factor1-8,10-13,15,16,18,20,22-24,26,31-33. In 
order to minimize confounding in the COBRA-study, we attempt to include a patient group and 
comparison group which were as similar as possible. To ensure that the two groups were as 
similar as possible with regard to social economic status, education level, and lifestyle factors, 
we recruited the participants in the comparison group via the patient’s network. In addition, 
both groups were matched on age to be able to assess changes naturally over time. Despite 
this method of recruitment, there were more highly educated women in the comparison 
group than in the patient group. Furthermore, women in the comparison group had a lower 
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BMI compared to patients. Therefore, women in the comparison group could be more health 
conscious. Because of the differences in education level and BMI, analyses of differences in 
dietary intake during chemotherapy between patients and comparison group were adjusted for 
different factors including education level and BMI in chapter 5. In chapter 4, changes in body 
composition between the two groups were adjusted for different factors including education 
level. Because BMI is highly correlated with body composition, we did not include BMI in these 
analyses. Including BMI in our analyses could therefore have led to overadjustment. 
Despite adjusting for various potential confounders, residual confounding can never be completely 
ruled out, because of unmeasured or inaccurately measured potential confounding factors. 
Selection error and bias
Selection bias can occur at different stages of a study; at the stage of recruitment of participants 
and/or during the process of retaining them in the study. Possible selection bias in these two 
phases of the study will be discussed in this paragraph.
Women in the patient group were included by the medical staff of participating hospitals. 
Recruitment via medical staff of hospitals could be a source of selection bias, since the staff 
decides which patient to invite. It is possible that patients who were more ill or more emotional 
at diagnosis did not get an invitation to participate in the study. Therefore, it is possible that the 
selection of breast cancer patients for our study is biased. 
Another potential source of selection bias may be the competitive studies conducted in breast 
cancer patients in hospitals in the Netherlands. In some hospitals various studies in breast cancer 
patients are conducted simultaneously. Therefore, some hospitals decided in advance which 
patients were asked for which study and which participants for another study depending on 
inclusion criteria. Therefore, it is also possible that a specific group of patients in a hospital was 
asked to participate in our study e.g. more patients receiving a particular type of chemotherapy 
or having a particular hormone receptor status. However, by recruiting in 11 hospitals, we expect 
this type of selection bias was limited in our study. 
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Participants in the comparison group were recruited via the patient group. Some patients were 
able to recruit several women, while others could not include anyone. Therefore, it is possible 
that the comparison group consists of specific women who are less comparable to the patient 
group. Nevertheless, women of both groups were quite similar, except in terms of education 
level and BMI.
Next to potential selection, also differential los to follow-up may lead to selection error. In the 
COBRA-study approximately 10% of the patients dropped out during the study period compared 
to 7% in the comparison group. Women in the patient group dropped out most often during or 
shortly after chemotherapy, due to illness during chemotherapy, or because the study burden 
was too high, while women in the comparison group dropped out because of a lack of time. 
When more women with more complaints during chemotherapy dropped out, this could have 
led to a group of patients with less complaints during chemotherapy. However, drop-out rates 
between the patient group and comparison group are quite similar within the COBRA-study.
Concluding information error and bias, confounding and selection error and bias may have 
slightly affected the internal validity of the COBRA-study. Nevertheless, the internal validity of the 
study appears to be high.   
External validity
If the internal validity is considered to be high as discussed in the previous section, the next step 
is to assess the external validity. External validity refers to whether results of our study can be 
generalized to the total population of breast cancer patients. 
In the patient population of our study 14% of the patients was diagnosed with a triple negative 
cancer, which is comparable with the results in the Dutch population where 15-20% is diagnosed 
with a triple negative tumour44. 
More than 50% of our participants in the patient and comparison group are classified as highly 
educated, whereas in the general Dutch population of women this was only 28% in 201245. 
This could be explained by the fact that high educated persons seem to be more willing than 
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lower educated persons to participate in studies46. We may expect that the participants in 
our observational study are more health-conscious than the general Dutch population, and 
therefore have a healthier diet and lifestyle compared to individuals not participating in this 
study. In addition, because of the recruitment procedure in the hospitals, it is possible that 
patients are more fit in relation to the total population of women diagnosed with breast cancer. 
As a result of this, our results might not be generalizable to all women diagnosed with breast 
cancer and the female Dutch population.
Changes in breast cancer care
Breast cancer care has changed over time. In this paragraph, we discuss two important changes 
in breast cancer care that have to take into account when comparing our results with previous 
studies; the first is the change in chemotherapy over time and the second is the awareness 
among clinicians.
The types of chemotherapy that are used in clinical practice has change over time. In our 
prospective study we found a mean weight gain of 1.1 kg during chemotherapy, which is similar 
to the 1.4 kg body weight gain we found in our meta-analysis, including only women treated 
with newer chemotherapy regimes. In addition, three recent studies, not included in the meta-
analysis showed no change, or only a slightly gain of 0.9 kg in eight during chemotherapy for 
early stage breast cancer26,27,29. Taken together, our meta-analysis, our prospective study and 
recent literature results suggest that weight gain during chemotherapy likely was greater in 
older studies as a result of changes in chemotherapy treatment.
Another possible explanation for less weight gain in more recent studies could be the clinicians’ 
awareness of possible changes in body weight and body composition during chemotherapy 
which may in turn lead them to better inform patients about possible changes during 
chemotherapy. Currently, many patients receive an invitation for an exercise program during 
and/or after chemotherapy e.g. fit en balans and herstel en balans. Because of participating in 
such a program it is possible that women are more active during the treatment and more aware 
of changes in body weight than those who are not participating in such program. 
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Conclusion
In conclusion, this thesis suggests that pre-treatment fat mass is associated with dose-limiting 
toxicities during chemotherapy. Weight gain during chemotherapy appeared to be more modest 
than we expected based on literature, and changes in body composition during chemotherapy 
consist mainly of an increase in lean body mass, which is only temporary and returned to baseline 
within 6 months after chemotherapy. A higher appetite during chemotherapy was associated 
with changes in body weight and body composition. A younger age at diagnosis was associated 
with greater changes in body weight and fat mass, but not with changes in lean body mass. In 
addition, an ER-receptor negative tumour was associated with greater changes in body weight, 
but not with changes in fat mass or lean body mass. During chemotherapy, women with breast 
cancer have a lower intake of energy, fat, protein and alcohol compared to age-matched women 
without cancer, which was expressed by a lower intake of specific food groups. The results of this 
thesis do not suggest that dietary intake is associated with weight gain during chemotherapy. 
Implications for clinical practice and future research
Despite the fact that this thesis suggests that weight gain is only modest currently, and the 
changes are temporary during chemotherapy but normalize in the 6 months after chemotherapy, 
it is still important for clinicians to inform patients about the potential changes in body weight 
and body composition. This is especially important for younger women. In addition, given the 
wide range in changes in body weight and body composition observed there are certain patients 
who will gain a lot of weight and change in body composition. Thus it remains important to 
monitor changes over time, especially since previous studies putatively suggested that changes 
in body weight and body composition may be associated with recurrence and mortality47-49.
A longer follow-up of the COBRA-study is recommended because of the following two reasons. 
First, in de patient group we found a trend toward an increase in fat mass during the 6 months 
after chemotherapy. A longer follow-up is desirable, to investigate whether fat mass in the 
patient group further increases and changes different from the fat mass in the comparison in 
the period after chemotherapy.
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The second reason is our inclusion of adjuvant and neo-adjuvant treated patients in our study. 
At the moment of the last measurements the patients in the neo-adjuvant group had just started 
their endocrine treatment, while the adjuvant group was receiving endocrine treatment usually 
already for several months. When following patients for a longer time, the effect of hormone 
treatment could be investigated within the COBRA-study.
Within this thesis we utilized only a portion of the data collected within the COBRA-study. 
Therefore, before starting a new study regarding changes in body weight and body composition 
in breast cancer further analyses within the COBRA-study can be conducted. For example, in 
addition to data on body weight, data on chemosensory changes were collected within the 
COBRA-study. A recent study suggests that patients who experience no, or mild chemosensory 
changes are the patients whose body weight remains stable, or who gain weight 50, but results 
are inconsistent 51. This could be further investigated within the COBRA-study, including other 
factors that may influence changes in body weight and body composition. At the moment of 
submission of this thesis, data collection for the COBRA-study was still ongoing. Therefore, not 
all data of all patients and women of the comparison group were included in the analyses of 
chapter 4. In due time, the analyses of chapter 4 will be repeated with the total study group, 
those analyses will have more statistical power to assess possible determinants of changes in 
body weight and body composition.  
The results on pre-treatment body composition and dose-limiting toxicities of this thesis  may 
not have direct implication for the clinical practice because consequences of administering 
chemotherapy based on body composition instead of body surface area are unknown. 
Furthermore, we were the first to assess the association of fat mass and dose- limiting toxicities 
during chemotherapy in breast cancer patients. Therefore, more research is needed to assess 
whether fat mass is indeed associated with dose-limiting toxicities and what consequences this 
may have on recurrence and disease-specific survival. 
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Summary
Because of the improved survival rate, both short term and long term adverse effects of breast 
cancer treatment have become increasingly important. Body weight and body composition 
before, during, and after chemotherapy may influence side effects during treatment and 
survival. The aims of this thesis were to assess among stage I-IIIB breast cancer patients: 1) 
the association between pre-treatment body composition and dose-limiting toxicities during 
chemotherapy, 2) potential changes in body weight and body composition during and after 
chemotherapy compared to changes in age-matched women without cancer in the same time 
period, and 3) dietary intake during chemotherapy compared to age-matched women without 
cancer in the same time period.  
Chapter 2 describes the association between pre-treatment body composition and dose-limiting 
toxicities during chemotherapy. Data from 172 breast cancer patients who participated in the 
COBRA-study were analysed. Body composition was measured using a total body Dual Energy 
X-ray Absorptiometry (DEXA) scan. Information regarding dose-limiting toxicities was abstracted 
from medical records. A higher BMI (kg/m2) and a higher fat mass (kg and percentage) were 
associated with an increased risk of dose-limiting toxicity, while lean body mass (kg) was not 
associated with risk of toxicities. 
Chapter 3 presents the findings of a meta-analysis on changes in body weight during 
chemotherapy in breast cancer patients. The meta-analysis showed an overall gain in body 
weight of 2.7 kg (95% CI: 2.0-3.3) during chemotherapy, with a high degree of heterogeneity 
(I2= 94.2%). Weight gain in breast cancer patients was more pronounced in papers published 
before 2000 and studies including cyclophosphamide, methotrexate and 5-fluorouracil as 
chemotherapy regime.
Chapter 4 describes changes in body weight and body composition during and after 
chemotherapy. Data from 145 patients and 121 women of an age-matched comparison group, 
participating in the COBRA-study were analysed. Body composition was measured using DEXA-
scan at three time points during the study period. For the patient group, these time points were: 
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before start of chemotherapy, shortly after chemotherapy, and 6 months after chemotherapy. 
For the comparison group these measurements were conducted over a similar time frame: 
baseline, 6 months after baseline, and 12 months after baseline. In addition, we identified 
determinants of changes in body weight and body composition.
Shortly after chemotherapy, patients had a significantly higher body weight, BMI, and lean 
body mass than women in the comparison group, while fat mass was similar. Six months after 
chemotherapy no differences in body weight or body composition were observed between the 
patient and comparison group. A younger age, better appetite during chemotherapy, and an 
ER-receptor negative tumour were associated with greater changes in body weight over time. 
A younger age and better appetite during chemotherapy were associated with greater changes 
in fat mass over time, while the only determinant associated with greater changes in lean body 
mass over time was a better appetite during chemotherapy.  
Chapter 5 describes the dietary intake and food groups before and during chemotherapy of 
breast cancer patients compared with women without cancer. In addition we assessed the 
association between symptoms and energy intake. Data from 117 breast cancer patients and 88 
women without breast cancer who participated in the COBRA-study were used. Habitual dietary 
intake before chemotherapy was assessed using a food frequency questionnaire. Two 24-hr 
dietary recalls were used to assess actual dietary intake during chemotherapy for patients and 
within 6 months for the comparison group. Shortly after the 24-hr dietary recall, participants 
filled out questionnaires about symptoms. Before chemotherapy, dietary intake was similar for 
both groups. During chemotherapy, breast cancer patients reported significantly lower total 
energy, total fat, total protein, and alcohol intake than women without cancer, which could be 
explained by a lower intake of specific food groups.
Overall results from this thesis suggest that pre-treatment fat mass is associated with dose-
limiting toxicities during chemotherapy. Weight gain during chemotherapy appeared to be 
more modest than we expected based on literature and changes in body composition during 
chemotherapy consist mainly of an increase in lean body mass, which is only temporary 
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and returned to baseline within 6 months after chemotherapy. A higher appetite during 
chemotherapy was associated with changes in body weight and body composition. A younger 
age at diagnosis was associated with greater changes in body weight and fat mass, but not with 
changes in lean body mass. In addition, an ER-receptor negative tumour was associated with 
greater changes in body weight, but not with changes in fat mass or lean body mass. During 
chemotherapy women with breast cancer have a lower intake of energy, fat, protein and alcohol 
compared to age-matched women without cancer, which was expressed in a lower intake of 
specific food groups. The results of this thesis do not suggest that dietary intake is associated 
with weight gain during chemotherapy.
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